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Fungal infections caused by Candida albicans pose a serious threat to public health. 
The rising drug resistance towards azoles, the current first-line antifungal treatment, 
warrants novel approaches to designing and delivering new antifungal agents that target 
C. albicans cells.  
To increase the intracellular delivery of bioactive molecular cargo, we studied 
the use of cell-penetrating peptides (CPPs) as delivery vehicles. CPPs have been 
extensively used to deliver different cargoes into mammalian cells, but limited work 
has focused on delivery into fungal cells. To improve understanding of CPP-mediated 
 
 
delivery to C. albicans, we studied their ability to deliver green fluorescent protein 
(GFP) intracellularly.  
For our work, we chose the CPPs, MPG and Hst5, that have previously shown 
translocation into fungal cells without cargo and recombinantly produced these CPP 
fusions to GFP in Escherichia coli. We investigated the CPP-mediated translocation of 
GFP using flow cytometry. Fusion of GFP to MPG resulted in translocation into 40% 
of C. albicans cells, which was significantly higher than 13% cells that demonstrate 
translocation of GFP without a CPP. However, Hst5 did not translocate GFP into cells, 
with only 5% of cells exhibiting Hst5-GFP translocation. Our results demonstrate that 
MPG can deliver GFP, while Hst5 is not as promising. These results are consistent with 
molecular dynamics simulations that show MPG enters a model membrane 
preferentially with the N-terminal residues, whereas Hst5 fails to enter the membrane. 
Our results emphasize the potential of CPPs in delivering large cargo to C. albicans 
cells and the advantage of using both experiments and simulations to study the 
translocation of CPPs into C. albicans. 
To explore factors affecting translocation efficacy, we evaluated the 
aggregation of CPP-GFP fusion constructs. Using dynamic light scattering and 
interference scattering microscopy, our results identified aggregation of our fusions at 
high concentration as a possible limitation to translocation, motivating future studies 
of the causes of aggregation and its relationship to translocation efficiency.  
Our work has shown that CPPs can deliver large biomolecular cargo into fungal 
cells and has laid the foundation for further studies to design better CPPs and to explore 
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Chapter 1: Background and motivation 
 
Fungal infections caused by the opportunistic pathogen Candida albicans (Figure 1.1) 
are a reason for concern for immunocompromised patients as they cause cutaneous and 
mucosal infections and systemic diseases5, 6. 
Infection due to C. albicans can be fatal, and 
growing drug resistance has contributed to 
ineffective treatment5, 7. Thus, new therapeutic 
approaches are needed. One important feature 
will be the ability of effectively and 
specifically being delivered across cell 
membranes to intracellular targets. Candida albicans is a dimorphic yeast organism 
(Figure 1.1) and can exist as unicellular round budding yeast cells or as multicellular 
elongated hyphae8 and is a well-known human pathogen that causes infections in 
people with compromised immune systems. For people with HIV/AIDS, people 
undergoing chemotherapy, and people with diabetes, C. albicans can cause serious 
systemic infections that are difficult to treat and have a high mortality rates9. Although, 
current antifungal agents exist toxicity and the increasing drug resistance are an issue 
which can delay the preliminary diagnosis of fungal infections 10, 11 and motivates 
finding of new approaches before resistance is a bigger problem than it is currently. 
 
Figure 1.1. Candida albicans in yeast 
and hyphal form. The scale bars 
represent 20 µm. Used with permission 








1.1 Fungal pathogen C. albicans and existing treatments 
 
Polyenes and azoles are the primary treatment options for fungal diseases7, 12 (Figure 
1.2). Amphotericin B, a polyene, has been recognized to cause significant kidney 
toxicity over extended period of use1, 12. Amphotericin B, interacts with the membrane 
sterol, ergosterol and produces aqueous pores containing an annulus of eight 
amphotericin B molecules that are coupled hydrophobically to the membrane sterols1, 
13, 14. This attachment forms a pore and the polyene hydroxyl residues face inward, that 
leads to transformed permeability, followed by escape of fundamental cytoplasmic 
components, and thus the death of the organism1, 15, 16. Polyenes have also been known 
to cause oxidative damage that aids in killing of C. albicans1, 17. 
 
  
Ergosterol is the important part of a fungal cell membrane18. The key target of 
azoles is the heme protein, which co-catalyzes cytochrome P-450-dependent 14α-
demethylation of lanosterol1, 19. When 14α-demethylase is inhibited, it leads to 
Figure 1.2. Antifungal drugs frequently to treat fungal infections caused by C. albicans. 








reduction of ergosterol and buildup of sterol precursors, that includes 14α-methylated 
sterols (lanosterol, 4,14-dimethylzymosterol, and 24-methylenedihydrolanosterol), and 
results in the formation of a plasma membrane with transformed structure and function. 
The antifungal activity of the azoles, fluconazole, itraconazole, and voriconazole, can 
be attributed to in part the inhibition of cytochrome P-450-dependent 14α-sterol 
demethylase 1, 20.  
 The Centers for Disease Control and Prevention (CDC), listed azole-resistant 
Candida species a reason for concern21. Candida pathogens become resistant to the 
azoles due to various reasons (Figure 1.3). For example, (a) target enzyme is 
overproduced, thus the drug does not impede the biochemical reaction completely; (b) 
drug target is changed so that the drug does not bind to the target; (c) an efflux pump, 
pumps out the drug; (d) access of the drug inside is stopped at the cell membrane or 
wall level; (e) cell takes a bypass pathway to balances for the loss-of-function inhibition 
due to drug action; (f) fungal enzymes that might convert an inactive drug to its active 









Though polyenes like amphotericin B, and azoles like fluconazole along with 
other drugs are efficient at treating fungal infections, their side effects and drug 
resistance mandate new therapeutic approaches. With continued use of these traditional 
treatments, the pathogen might develop more robust mechanisms to resist the fungal 
therapies thus increasing the risks of infection and thus fatality. This warrants the study 
of newer and novel drugs and drug delivery vehicles that that can cure fungal infections 
without causing the side-effects or drug resistance.  
Figure 1.3. Schematic representation of reasons for resistance to azoles. The reasons include 1) 
Target enzyme is overproduced 2) Drug target is changed so that there is no binding 3) Efflux pump, 
pumps the drug 4) Entry prevented at cell membrane or cell wall 5) Compensation of loss-of-
function inhibition by bypass 6) inhibition of fungal enzymes that converts inactive drug to its active 
form 7) Secretion of enzymes to the extracellular medium that degrades the drug. Figure reprinted 






1.2 Cell-penetrating peptides (CPPs) 
 
Though current antifungal 
treatments exist, due to 
problems associated with these 
treatments, we propose the use 
of cell-penetrating peptides 
(CPPs) as delivery vectors to 
transport our cargo inside the 
cells. As compared to other 
methods like microinjection, electroporation and magnetofection (biophysical 
methods) or use of amphipathic detergents (biochemical methods), and viral vectors22, 
23, CPPs can efficiently enter cells in a noninvasive and safe manner without destroying 
the integrity of the cellular membranes23. Consequently, this opens up newer 
possibilities for research in life sciences23, 24. Cell-penetrating peptides are short 
peptides, about 30 amino acids in length, mostly cationic, have the ability to cross cell 
membranes, and at the same time carry small biomolecular cargo across the barrier23, 
25-27 (Figure 1.4). These CPPs are also known as protein translocation domain (PTD) 
or Trojan horse peptides. These peptides are comparatively less toxic as compared to 
other drug delivery vehicles like virus vectors and can be easily synthesized, 
characterized and functionalized27-30. These CPPs have transported various cargoes like 
Figure 1.4. Cell penetrating peptides and mechanism of 
cell entry. Figure adapted from Singh et al.6 (Open 







DNA, proteins, nanoparticles and small molecules and thus can be used to  target 
intracellular targets which is necessary for their biological activity 31-37 37, 38,39-43. 
 
1.3 CPPs, their classifications and mechanism of entry 
 
CPP can be classified into different categories based on their origin or their physical-
chemical character. Based on origin, CPPs can be divided into either protein-derived 
or synthetic; whereas based on their characteristics these CPPs can be divided into three 
subgroups: amphipathic, cationic and hydrophobic (Table 1 lists some examples of 
various CPPs)44. Further, they can be classified as primary amphipathic, secondary 
amphipathic and non-amphipathic based on their sequence, length, and association with 
lipids44, 45. Primary amphipathic peptides such as pep-1 and TP10 have hydrophobic 
and cationic residues segregated at the sequence level46-50. On the other hand, in 
secondary amphipathic CPPs like penetratin, cationic and hydrophobic residues are 
only segregated when the peptide folds into a secondary structure51. We are studying 
the use of CPPs which have the ability to cross cellular membranes by experimental 
and computational methods (Figure 1.4)52,53,54,29,55. Cationic CPPs do not interact with 
uncharged model membranes and does not interfere with the integrity of the plasma 
membrane of cells23, 49, 50, 56. On the contrary, primary amphipathic CPPs interact with 
model neutral membranes and when they interact with the plasma membrane, it 






concentrations, amphipathic CPPs stimulate the influx of Ca2+ ions into the cytosol. 
This influx triggers a repair response by the cells44, 57.  
 
Table 1.1 Cell-penetrating peptides, their origin and type (selected information is 
reproduced from Pooga et al.44) 
 
Sequence Name (origin) Typea Reference 
Cationic 
RKKRRQRRR HIV-1 pTat(49–57) N 58 
RRRRNRTRRNRRRVRb FHV coat N 59,60 
TRQARRNRRRRWRERQRb HIV-1 Rev N 59,127 
RQIKIWFQNRRMKWKK Penetratin N 52 
(R) n b; n = 6–12 Polyarginine S 59,46 
Amphipathic 
LLIILRRRIRKQAHAHSKb pVEC N 61 
KFHTFPQTAIGVGAPb hCT peptide18-32 N 62 
KETWWETWWTEWSQPKKKRKVc Pep-1 C 63 
GALFLGFLGAAGSTMGAc MPG C 33 
GWTLNSAGYLLGKINLKALAALAKKILb Transportan C 64 
AGYLLGKINLKALAALAKKILb TP10 (transportan 
analogue) 
C 65 
KLALKALKALKAALKLAb MAP (model 
amphipathic peptide) 
S 66 
QLALQLALQALQAALQLA MAP17 S 67 
Palmitoyl-KIHKKGMIKS F2Pal10 S 68 
Hydrophobic 
AAVLLPVLLAAP K-FGF N 69 
PFVYLI C105Y N 70 
SDLWEMMMVSLACQY Pep-7 S 71 
PLILLRLLRGQF Pept1 S 72 
Anionic 
LKTLTETLKELTKTLTEL MAP12 S 73 
VELPPPVELPPPVELPPP SAP(E) S 74 
aN natural, C chimeric, S synthetic; bC-terminal amide; cC-terminal cycteamide 
 
There are different mechanisms for translocation of CPPs into cell membranes 






be through direct translocation75, endocytic or non-endocytic routes. Endocytic routes 
of translocation comprise macropinocytosis, clathrin-mediated endocytosis, 
caveolae/lipid raft-mediated endocytosis, and clathrin/caveolae-independent 
endocytosis38, 76, 77. Endocytosis is the method by which cells take up living matter and 
form a vacuole. Clathrin-mediated endocytosis and caveolae-mediated pinocytosis are 
both receptor-mediated endocytosis processes which need membrane receptors to 
allow vesicles formation78 for example receptors like receptors for growth factors and 
G-protein coupled receptors whereas the process of micropinocytosis, does not need a 
receptor79. An inverted micelle model, carpet model, and the pore formation model are 
part of the non-endocytic routes30, 80. For the inverted micelle model, the CPPs with 
hydrophobic amino acids are critical for the translocation process80. Electrostatic 
interactions between the CPP and the negatively charged membrane phospholipids 
leads to insertion into the membrane, and the interaction leads to formation of vesicles 
and capture of the CPP81. In the carpet model, the peptide binds to negatively charged 
phospholipids, is followed by rotation of the peptide that allows interaction between 
the hydrophobic residues of the peptide and the membrane. Subsequently, a disruption 
in the packing of the membrane allows internalization of the peptide28. The pore 
formation or barrel-stave model relates to development of bundles by amphipathic α-
helical peptides. The barrel-stave model is typical of amphipathic α-helical peptides - 
the peptides form bundles after their interaction with the cellular membrane 
(membranes have channels in the centers)23. A pore forms due to the interaction 






outward, with the lipid membrane23, 28. This interaction happens at concentration of the 
peptides  that is higher than a threshold concentration (this concentration differs for 
each peptide)28. A toroidal model pertains to peptides that can form α-helices as they 
come in contact with cell membranes. In this type of model, the positive side chains of 
the peptide interact with the membrane phosphate groups, leading to the buildup of the 
peptide on the external leaflet of the membrane23, 82. The peptides at this point causes 
twisting of the lipid monolayer into the inside, that forms a hydrophilic break in the 
membrane, wherein the phospholipid heads and peptides are found23, 82. Peptides like 
MAP, SynB, PAF26 are transported by energy-dependent endocytic mechanisms; 
pVEC and penetratin employ micropinocytosis while others like MPG and Pep-1 
undergo pore formation47, 66, 83-87.   
 
1.4 CPP as delivery vectors 
 
The first CPP Tat was first revealed in 198958, 88, and since then researchers have 
extensively studied CPPs to utilize them as delivery vectors34, 89. CPPs have favorable 
advantages and can deliver cargoes with high efficiency and specificity89. CPPs can 
deliver a variety of biomolecules that includes DNA, siRNA, proteins, and 
nanoparticles31-37 38-43. CPPs have been seen to also deliver contrast agents for example 






peptide when it is covalently conjugated to the peptides either by chemical reaction or 
recombinant expression.  
 
 
1.4.1 Delivery of proteins as a cargo 
 
Peptides and proteins can be useful as therapeutics and thus can help cure infections 
and diseases. Researchers have been using CPPs to transport protein cargos of variable 
sizes that range from 25 kDa for example scFv41 to a size of 150 kDa that includes 
IgG40. Delivery of antibody fragments by CPPs like Tat and penetratin have shown 
tissue localization in vivo 92. CPPs have also been shown to be effective in delivering 
therapeutic proteins to treat cancer and strokes for example, Tat and penetratin have 
delivered elastin-like polypeptides that is fused to a cyclin-dependent kinase inhibitor 
that inhibited the growth of cancer cells93. CPPs have been useful in delivering to 
various types of cells that include mammalian, fungal and bacterial cells42, 94, 95 and 
thus can be used for drug delivery.  
Penetratin has also been used to reduce blood glucose concentration. On 
administering insulin and penetratin simultaneously in rats, it led to a considerably 
higher increase in bioavailability and reduction of blood glucose, while just insulin 






show that on successful delivery of proteins inside cells with CPPs, many diseases can 
be targeted and cured. 
 
 
1.4.2 Delivery of nucleic acids as a cargo 
 
CPPs can deliver siRNA, antisense oligomers, and plasmids but intracellular transport 
is sometimes limited due to high molecular weight and negative charges, making the 
regulation of gene expression easier98. Recombinant lactaptin has been shown to 
deliver noncovalently bonded nucleic acids into cancer cells in vitro99. Various CPPs 
like transportan, penetratin, amphipathic peptides (for example MPG), and 
polyarginine have been used considerably, to deliver siRNA into animal and plant 
cells32, 100-108,48,109. When CPPs cross the cell membrane and deliver macromolecular 
cargoes, the process is known as protein transduction110, 111. Stearylation of arginine-
rich CPPs have shown to drastically increase transduction efficiency of plasmid 
DNA112, 113. CPPs like Tat has been used to carry the gene for GFP into mammalian 
cells with a high transfection efficiency and biological activity114. MPG has been shown 
to deliver siRNA into mammalian cells, that enabled fast release of the siRNA into the 
cytoplasm and promoted robust down-regulation of target mRNA105. These examples 
show how CPPs, when conjugated covalently or non-covalently with nucleic acids, can 






1.4.3 Delivery of nanoparticles as cargo 
 
In general, treatment of diseases with drugs can lack specificity and can have toxic 
side-effects. Thus, CPPs have been studied in conjunction with nanoparticles for 
treatment of cancer. TGN when conjugated to poly (ethyleneglycol)-poly (lactic-co-
glycolic acid) (PEG-PGLA) nanoparticles, was able to cross the blood brain barrier and 
transport coumarin-6 as a probe into the brain at 3.6-fold times higher than 
nanoparticles alone115. To further study the effects off CPP-conjugated nanoparticles 
delivery, researchers synthesized a self-assembled drug-polymer that consisted of 
MMP2 cleavable peptide and TAT protected by PEG and Paclitaxel. The nanostructure 
accrued in the tumor sites and when the cleavable MMP2 peptide was broken, it 
exposed the TAT that helped cell internalization followed by drug release116, 117. In 
another study, Wang et al. have used cationic antimicrobial peptides to treat multiple-
drug resistant infections118. They studied the cholesterol-conjugated G3R6TAT 
(CG3R6TAT) cationic nanoparticles, and demonstrated the use of nanoparticles for 
treatment of Cryptococcus neoformans (yeast)-induced brain infections. The antifungal 
activity of the nanoparticles was compared with amphotericin B and fluconazole. 
Minimum inhibitory concentrations (MICs) of the nanoparticles were measured and 
they found them to be much lower than those of fluconazole but marginally higher than 
those of amphotericin B in some samples. The nanoparticles were shown to entirely 






study showed that CG3R6TAT nanoparticles are a promising antifungal agent for 
treatment of brain infections. 
 Quantum dots (QD) have previously shown to have poor penetration in cells 
but researchers have been able to overcome that when attached to a CPP. This work 
showed that when QD was conjugated with arginine-rich CPP, they were taken up by 
living cells in vitro 119. All the above examples show the innumerable applications of 
CPPs and thus these can be used to effectively deliver nanoparticles and can be used as 
imaging agents. 
 
1.4.4 Delivery of small-molecule drugs as cargo 
 
CPPs have been shown to increase the efficiency of small-molecule drugs120, 121. For 
example, to mitigate the resistance to chemotherapy, and to ensure effectiveness of 
anti-cancer drug treatment, a CPP-drug conjugate, with the drug cytostatic agent 
methotrexate (MTX) was prepared120. It was seen that at a concentration of 1 μM, the 
CPP–MTX conjugates overcame the MTX resistance and killed the cells more 
effectively than MTX alone120. In another study, polyarginine conjugates of a 
hydrophobic drug Paclitaxel showed improvement in water solubility and cellular 
uptake121, 122. Penetratin has delivered a photoactive drug, a pro-drug 5-aminolevulinic 






was possible due to penetratin. These examples show that CPPs can be used to enhance 
properties of drugs and increase their usefulness. 
The examples above outline the different applications of CPPs, but these have 
mostly been studied in mammalian cells, and very little information exists on 
translocation into other types of cells, like bacterial and fungal cells42, 94, 124, 125. To 
better understand the CPP-mediated delivery of larger biomolecular cargo and their 
limits in translocation, a more detailed study is required. Gong et al., recently studied 
the translocation mechanism of CPPs into the fungal pathogen C. albicans. This study 
gives us a better idea on designing better CPPs and ways to design the to enhance 
translocation126, 127. In the present study, we will use CPPs for delivery of proteins into 
the fungal pathogen, C. albicans. 
 
1.5 Overview of thesis 
 
In this dissertation, I describe my work to study CPPs and their delivery of a protein 
cargo into fungal cells. Current antifungal treatments can cause toxicity or the 
pathogens can develop resistance to the drugs and this warrants for research into newer 
therapeutic approaches. In this chapter, I outline characteristic features of CPPs, cell 
entry mechanisms of CPP-mediated cargo delivery and delivery of various types of 
cargo. In Chapter 2, I review protein engineering strategies and peptide properties to 






fluorescent protein into Candida albicans cells. This chapter also talks about effect of 
cargo on overall secondary structure with some initial CD studies. Chapter 4 expands 
on the work presented in Chapter 3 by incorporating molecular dynamics simulations 
done by Jeffery Klauda’s Lab to rationally design CPPs and test their delivery efficacy 
by experimental methods. In Chapter 5, I present my study on aggregation of proteins 
and how aggregation can affect translocation. In Chapter 6, I present some initial data 
on alternate methods to detect delivery of fluorescent and non-fluorescent cargo, and 
summarize my work and discuss future directions for research based on my studies in 
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Chapter 2: Methods to engineer peptides1  
 
Peptides are a promising source of new therapeutics, but the biophysical characteristics 
of natural peptides, including their stability and propensity to aggregate, can limit their 
success. Protein engineering offers powerful tools to improve the properties of peptides 
for biological applications. In this chapter, we discuss rational design, directed 
evolution, and computational methods and how these methods can be applied to 
improving the characteristics of peptides. We provide a discussion of engineering the 
thermodynamic stability, self-assembly, reduced aggregation, proteolytic stability, and 
binding affinity and specificity of peptides and provide a perspective on future 




Naturally-occurring peptides serve important roles in human physiology, including 
functioning as hormones, neurotransmitters, growth factors, and anti-infectives2. In 
these roles, peptides exhibit powerful biological activity and specificity, making them 
appealing for the development of potential therapeutics2, 3. In fact, the use and 
 
1 The various subsections (2.1, 2.2, 2.3, 2.4) of this chapter have been adapted from the AICHE special 
edition review 1. Adhikari, S.;  Leissa, J. A.; Karlsson, A. J., Beyond function: Engineering improved 
peptides for therapeutic applications. AIChE Journal 2019, 66 (3), e16776. (Reproduced with 






development of peptide therapeutics continues to grow, with more than 60 approved in 
the United States and 260 peptides in active, human clinical trial development as of 
20174. Peptides have consistently demonstrated high levels of intrinsic safety, 
tolerance, and efficacy, which can lead to improved performance over small molecules 
in clinical trials 2, 4, 5. Important approved peptide therapeutics include leuprolide, a 
gonadotropin-releasing hormone analog approved for treating advanced prostate 
cancer, and insulin glargine, a long-acting analog of insulin approved for treating type 
I and II diabetes. These peptides represent two of the most successful examples of 
peptide therapeutics, with the leuprolide drug Lupron® achieving US$892 million in 
worldwide net sales in 20186 and the insulin glargine drug Lantus® achieving €3.57 
billion (~US$4.0 billion) in the same year 7. 
 Although peptides have many appealing characteristics, challenges associated 
with their physiochemical properties can present barriers for their use in medicine8. For 
example, peptides can be degraded in vivo through a multitude of endogenous 
proteases3, making it difficult for the successful delivery of intact peptide to the desired 
site8. This is especially of concern for orally administered therapeutics because of the 
combined high proteolytic activity and low pH in the gastrointestinal tract, which 
intensify degradation8. Additionally, some natural peptides have a propensity to 
aggregate and are poorly soluble in water, limiting their bioavailability2. Because of 
these limitations, applying engineering approaches to explicitly address biophysical 






 By considering these fundamental properties, novel peptides can be designed 
with fitness properties improved compared to natural peptides3. Although the peptide 
sequence space is limited compared to proteins, ample mutational diversity to develop 
improved or new peptide-based therapeutics is available through canonical amino 
acids, post-translational modifications, and secondary structure geometries3. In this 
chapter, we provide an overview of methods used to engineer biophysical 
characteristics of peptides. We focus on engineering peptides by introducing amino 
acid changes into the primary sequence of peptides using canonical amino acids and 
screening for improvements to a desired characteristic. (Recent reviews explore non-
natural amino acids in peptide therapeutics and in protein engineering9, 10.) We then 
discuss how these methods have been used to improve biophysical characteristics and, 
thus, therapeutic potential of biologically active peptides. Finally, we discuss 
opportunities for improving our ability to engineer peptides that have the necessary 
properties for therapeutic applications. 
 
2.2 Approaches for introducing and screening diversity 
 
A typical approach to designing therapeutic peptides involves starting with a peptide 
sequence with a desired biological function. Based on what is known about the 
structure and function of the peptide, one or more characteristics of the peptide to be 






that improve the fitness and therapeutic potential of the peptide. Changes to the amino 
acid sequence are introduced in a specific or random manner, and these changes are 
evaluated to screen for modifications that lead to the desired improvement in the 
characteristic(s) being engineered. Experimental approaches used to introduce changes 
to the amino acid sequences and screen their effect on the properties of interest can be 
categorized as rational design or directed evolution, and these approaches can also be 
applied through or assisted by computational methods (Figure 2.1). When undertaking 
a peptide design project, considering the advantages and disadvantages of each strategy 
is important in selecting the route that will be used to engineer the peptide.  
 
2.2.1 Rational design 
 
 
Figure 2.1. Selection of the approach to use to engineer a peptide to meet specific design criteria 
requires understanding the available approaches and determining which technique(s) best suit the 
available knowledge. Often, an engineering strategy will incorporate elements of multiple 







Rational design is commonly selected to engineer peptides when prior knowledge 
regarding structure-function relationships exists. With this knowledge, rational choices 
are made regarding which residues to change and to which amino acids they should be 
changed3. Rational design is typically performed with discrete mutations, generating a 
small library of variants. Because of the small library size, the variants often can be 
individually evaluated for the effect of the amino acid changes on the desired 
characteristic with standard, relatively low-throughput assays for the characteristic of 
interest. Rational design allows a deeper understanding of the importance of 
physiochemical interactions at a given position, as mutations that both improve and 
reduce fitness can be assessed because of the small library size. Additionally, 
information regarding structure-function trends in similar peptides or proteins can be 
applied through rational design to improve a peptide of interest. For example, Joshi et 
al. rationally designed mutations in a synthetic peptide based on current small molecule 
inhibitor therapeutics to map the substrate selectivity of aminopeptidase N (APN), an 
extracellular membrane-anchored enzyme overexpressed in cancerous cells11. Using a 
combination of crystallography and mass spectrometry, the authors analyzed variants 
of a substrate peptide that incorporated substitutions around the enzyme cleavage site 
and developed an understanding of the interactions required for substrate recognition 
by the enzyme. The process also identified a peptide inhibitor that is effective at 
inhibiting the degradation of a known APN substrate both in vitro and in vivo in prostate 






structure-function data and to use that data to design peptides for therapeutic 
applications. 
 
2.2.2 Directed evolution 
 
Directed evolution, which mimics the process of natural selection, is another important 
approach used to improve the properties of peptides for therapeutic applications. In 
directed evolution, a large library of peptide variants, which can be on the order of 1010-
1014 variants12, is generated by introducing random or targeted variation into the gene 
for the peptide of interest. The library is subjected to successive rounds of screening 
and mutagenesis, where a promising mutant or mutants isolated from a given round are 
used as the foundation for mutagenesis in the next round13. Iterations continue until one 
or more mutants have the desired fitness with respect to a given property14, 15. Unlike 
rational design, where all variants are normally assessed, the focus in directed evolution 
is typically on those variants that show improvement in the characteristic being 
engineered. 
 In a directed evolution strategy, one of the main challenges is designing a screen 
for the property or properties being engineered that allows interrogation of the large 
number of library members required to find desired variants. The time to assay 
individual library members in complicated assays is typically prohibitive for the library 






addressed in directed evolution is a screen suitable for assaying a large peptide library 
within a reasonable time. The screen must address two challenges: (1) it must be 
properly designed to effectively screen for the desired characteristic16 and (2) it must 
incorporate a method to link the gene sequence of the peptide (genotype) to the quality 
of the characteristic being engineered (phenotype). Sometimes, a screen can simply 
take the form of a 96-well plate assay, where cells producing a single peptide variant 
are placed in each well, and the characteristic being engineered is assayed in the well. 
Since only a single variant is in each well, the linkage of the genotype to the phenotype 
is maintained through the assay. This type of screen has the advantage of being able to 
use any type of assay that can be performed in a 96-well plate, but, even with the use 
of automation, screening a sufficient number of variants in large libraries is still 
prohibitive. To overcome this limitation, a powerful tool called surface display can be 
used for screening libraries in directed evolution. 
 In surface display, library members are physically anchored to the surface of a 
cell or biological molecule, where they can be interrogated for properties of interest, 
including biophysical properties. The physical linkage conserves the genotype-to-
phenotype linkage, allowing the properties of a selected variant to be directly traced 
back to the sequence that generated it to identify the amino acid changes responsible 
for changes in the peptide’s behavior. Additionally, these systems are attractive because 
they are easy to use in conjunction with soluble ligands that can be used as reporters 
for activity or fitness, making them suitable for quantitative analysis with high-






(FACS),18 and biopanning19. Two types of surface display technologies exist: cell-
surface display and in vitro display. In cell-surface display, a variant is expressed by a 
cell and anchored to the surface of the cell through a membrane or cell-wall protein, 
establishing the genotype-to-phenotype linkage. Expressing the variants in a library on 
the surface of individual cells allows the library to be easily interrogated for desired 
characteristics, and the DNA encoding for a desired variant can be recovered after 
growing the cell or performing PCR. Several different cell-surface display systems 
have been used for directed evolution of peptides, including systems involving display 
on phage20-22, yeast23-25, and bacteria26-29. One of the main limitations of cell-surface 
display systems is that the library size is limited by the transformation efficiency of the 
cells involved in the display. Still, given the sequence space for peptides is smaller than 
for larger proteins, they remain very useful methods in engineering peptides30-32. 
 Common in vitro alternatives to cell-surface display include ribosome display 
and mRNA display. In ribosome display, ribosome stalling is used to conserve the 
mRNA-ribosome-peptide complex after translation33. RNA display utilizes a 
puromycin linkage in place of the ribosome to covalently bind the mRNA and resulting 
translated peptide. Both methods lead to covalent linkage of peptide variants to the 
nucleic acids encoding their sequence, so the sequence for library variants that have 
desired characteristics is easily recovered. While in vitro systems are more expensive 
than cell-surface display systems, in vitro display can investigate a larger library size 






 Cell-surface display and in vitro display bring an ability to screen large numbers 
of variants to directed evolution, but another tactic often incorporated in directed 
evolution is to reduce the library size to reduce the resources needed to screen the 
library. Structure and function data are used to identify specific regions, residues, or 
residue types of interest to limit the number of residues that are varied. Saturation 
mutagenesis and patterned libraries are two examples of strategies that take advantage 
of this combination of rational design and directed evolution. In site-saturation 
mutagenesis, all 20 canonical amino acids are sampled at the residue(s) of importance 
and the resulting peptides are screened for desirable fitness. Reetz et al.’s method of 
iterative saturation mutagenesis (ISM) expands on this idea35-37. After identifying 
important sites containing 1-3 amino acids, the amino acid(s) in each site are subjected 
to site-saturation mutagenesis and the resulting libraries are each screened to identify 
the best mutant in each library. The best mutants from the first round are then subjected 
to site-saturation at each of the other sites to generate multiple new libraries based on 
each of the best mutants. The screening and mutagenesis continue until mutants with 
the desired properties are identified. While the applications of ISM have so far focused 
on evolving proteins, this technique also has promise for engineering peptides. 
Patterned libraries take advantage of the known interactions between polar and non-
polar residues to limit library size while maintaining or introducing desired secondary 
structure of the resulting peptide library. Because the periodicity of α-helices and β-
sheets is known, the location of polar and non-polar residues can be fixed, while 






design a peptide library containing peptides with different combinations of short a-
helical and b-sheet segments and then screened for binding affinity to streptavidin with 
mRNA display to isolate peptides with binding affinities as low as 5 nmol/L42. As these 
library design methods illustrate, rational design and directed evolution principles often 
combine to yield effective experimental methods to improve peptide functions. 
 
2.2.3 Computational methods 
 
Rational design and directed evolution are powerful experimental approaches for 
peptide engineering, and improvements in structure-function knowledge and 
improvements in computational tools have allowed the principles of these approaches 
to be employed through computational design43, 44. Computational methods simulate 
experimental conditions, offer guidance for designing libraries, and help explain the 
influence of mutations on the characteristics of peptides. Due to these benefits, the use 
of computational methods continues to increase in peptide engineering and in protein 
engineering more generally.  
 Molecular dynamics (MD) simulations study physical movements of 
interacting atoms and molecules over time, making them valuable tools for 
understanding and improving properties of peptides. Atom-specific information is 
generated at each time-point, allowing identification of residues or domains important 






(typically µs)45, 46, which is not always sufficient to observe desired biological 
phenomena47, 48. Coarse-grained simulations can be used to resolve this time-scale 
limitation through lower resolution and reduced atomic details, though results need to 
be confirmed with more sophisticated simulations to ensure predictive adequacy49. 
Course-grained and all-atom methods can also be combined to allow larger system 
sizes and longer time-scales compared to purely atomistic models. For example, 
Shelley et al. studied the aggregation of the antimicrobial peptide melittin in aqueous 
solution using an all-atom representation for melittin and a course-grained 
representation for water molecules and ions50. By using a course-grained representation 
of the solvent, the authors reduced the computational time for the simulations compared 
to a fully atomistic simulation, while still obtaining aggregation and structural data that 
aligns well with experimental observations.  
 Machine learning can also be used to design for improved characteristics of 
peptides relevant for therapeutic applications. With this method, a database of peptides 
with known sequences and performance with respect to the desired characteristic of 
interest is required. The database is used to train the model by identifying patterns in 
the provided peptides. After training the model, the algorithm can generate a list of 
promising new peptides that meet the desired criteria. In this way, machine learning 
mimics directed evolution by selecting peptide sequences most likely to have desirable 
fitness51-54. Fjell et al.’s work screening for potent antibiotic peptides illustrates how 
machine learning can be applied to peptide design51. The authors first evaluated the 






descriptors of structural properties (e.g., charge, hydrophobicity) for each peptide. 
Using this database of peptides, the machine-learning model was then trained to 
determine whether a peptide has antibacterial activity by using the quantitative 
descriptors and the experimentally determined activity levels. After training, the model 
screened a virtual library of nearly 100,000 peptides based on their descriptors and 
successfully identified peptides with strong antibacterial activity, highlighting the 
power and potential of machine learning in designing peptide therapeutics. 
 Another method commonly used to engineer peptides is computer-aided protein 
directed evolution (CAPDE). In this method, computational simulation tools are 
utilized to assist in directed evolution. CAPDE has been used to characterize libraries 
that are generated by mutagenesis, to design libraries based on evolutionary and 
structural information of target proteins/peptides, and to predict the effect of mutations 
on the structure and function of the protein55. CAPDE and other computational methods 
are helpful in narrowing the set of sequences to be analyzed experimentally, which can 
reduce experimental time and resources and reduce or eliminate the need for high-
throughput experimental methods.  
 
2.3 Protein engineering to design peptide characteristics 
 
When identifying or designing peptides as potential therapeutics, the biological 






function is linked to characteristics of the peptide that govern its interactions with itself, 
its interactions with other molecules, and its stability (Figure 2.2). Purposefully 
designing peptides to address these biophysical characteristics can improve the 
therapeutic potential of peptides, and rational design, directed evolution, and 
computational tools are well suited for this design. Here, we describe how protein 
engineering can be used to design peptides with improved characteristics, in terms of 
thermodynamic stability, self-assembly, reduced aggregation, proteolytic stability, and 
binding affinity and specificity. 
 
 
2.3.1 Thermodynamic stability 
 
Thermodynamic stability is important for in vivo applications of peptides, as a peptide’s 
ability to retain its structure can influence its efficacy. For example, the antimicrobial 
Figure 2.2. Designing peptides for therapeutic applications requires consideration and engineering 
biophysical characteristics, in addition to the biological function (Reproduced with permission,  







activity and immunogenicity of peptides can rely on their ability to form and retain 
their secondary structures56, 57, so engineering higher thermodynamic stability can be 
crucial for their in vivo efficacy. When engineering a peptide for thermodynamic 
stability, a key consideration is whether the peptide contains α-helical58-60 or β-sheet61-
63 secondary structure, as knowledge of the intramolecular interactions in these 
structures assists in designing or improving peptides.  
 Forming an α-helical structure can stabilize a peptide60, 64, and rational design 
can be used to improve the propensity to form α-helices and the stability of the helices. 
Using rational design, α-helicity can be engineered via intramolecular salt bridges using 
Glu, Asp, Arg, or Lys salt bridges to increase helicity58, 59. To better understand how 
salt-bridges affect stability, Wolny et al. designed de novo, single α-helix peptides with 
the motif AEEEXXX (X = K or R)60. Experimentally, they showed the sequence 
AEEEKRK is more helical and thermostable than AEEEKKK, suggesting that Arg 
increases stability compared to Lys. Molecular dynamics simulations of the peptides 
indicated that the improved helicity and stability of the peptide with Arg is likely due 
to salt bridges being formed more readily and frequently between Glu and Arg than 
between Glu and Lys, because Arg has a larger range of rotamer conformations and the 
guanidium group on the Arg side chain leads to increased interactions with Glu. This 
effect is not limited to small peptides. Substitution of Lys with Arg in the single α-helix 
of the naturally occurring protein myosin-6 increased its stability, whereas the 






helix peptides can also be observed in the context of more complicated proteins or 
peptides.  
 The β-sheet structure of a peptide can also be stabilized through salt bridges and 
other interactions. For example, Bureau et al. compared the energetics between two 
small stable β-hairpin peptides, trpzip1 and chignolin using MD simulations62. The 
peptides have comparable secondary structures and hydrogen bonding profiles, but 
their stabilities and melting temperatures are dissimilar. Forced unfolding energetics of 
trpzip1 revealed the peptide is more stable than chignolin, meaning more work is 
required to stretch the peptide from a primarily folded state to an unfolded state. This 
was attributed to the presence of the E5-K8 salt bridge located near the b-hairpin turn 
point in trpzip1, since it was the most energetically favorable side chain interaction in 
the peptide and helped initiate and maintain the hairpin structure62. π-π stacking can 
also be important in stabilizing peptides by segregating the hydrophobic core from the 
surrounding aqueous environment. In a synthetic antimicrobial peptide utilizing repeats 
of the motif (WRXXRW), where XX represents the turn sequence, the Trp residues in 
the motif further stabilize the β-hairpin structure of the peptide through π-π stacking61. 
Stabilizing the secondary structure resulted in a higher bacterial selectivity, less salt 
sensitivity, and stronger activity, all of which improved with additional repeats of the 
motif61. Additionally, Capelli et al. observed that this interaction was crucial for the b-
hairpin structure of the immunoglobulin-binding domain peptide GB1, as Ala 
screening demonstrated that the removal of Phe, Trp, and Tyr participating in π-π 






 To this point, designing peptides for thermodynamic stability has mainly used 
rational design, sometimes with the assistance of computational methods that apply 
knowledge of intramolecular interactions. Directed evolution has not played a 
significant role in the design of peptides for thermodynamic stability, though it is 
widely used for larger proteins65-68. The two main techniques used to improve the 
thermodynamic stability of proteins involve exposing a protein library to heat prior to 
evaluating function and screening for solubility or expression as surrogate for 
stability65-68. Bond et al. and Julian et al. employed another successful strategy, which 
involved using a ligand (Protein A) that binds only to library members (single-domain 
antibodies) when the library members are well folded69, 70. The methods used for larger 
proteins should have utility for peptides as well, and combining these techniques with 





Self-assembly produces highly ordered structures with assembly of nanoscale building 
blocks of all length scales. Nearly all self-assembled structures, including peptides, are 
thermodynamically stable compared to single unassembled structures71, and assembly 
of peptides can also improve other important characteristics, including responsiveness 






73. Self-assembly of peptides into ordered nanostructures is important in various 
therapeutic applications, including antimicrobial activity72, tissue grafting74, drug 
delivery75, 76, and vaccine design 74, 76-80. In addition to modulating assembly conditions 
to control self-assembly75, 76, 78, the design of the peptide sequence can also be used to 
tune the assembly of peptide monomers into nanoscale structures.  
 Molecular interactions play an important role in forming stable, self-assembled 
structures, so selection of the residues and sequence of a peptide affect the structures 
that are formed through assembly. To understand how molecular interactions lead to 
the self-assembly of twisted, helical, and flat nanostructures, Zhou and Deng et al. 
compared the self-assembly process for three different rationally designed peptides 
with the same amino acid composition but different sequences81. KE-F8 (NH2-
KEFFFFKE-CONH2) and EK-F8 (NH2-KEFFFFEK-CONH2) differ only by the two 
C-terminal, charged residues, whereas KFE-8 (NH2-KFEFKFEF-CONH2) has the 
hydrophobic and charged residues uniformly distributed throughout the sequence. The 
sequence of each peptide was designed to elicit a specific molecular packing due to the 
interactions within and between β-sheets. Using transmission electron microscopy 
(TEM) and atomic force microscopy (AFM), the authors showed that KE-F8 form 
twisted ribbons, EK-F8 forms helical ribbons or tubes, and KFE-8 forms flat ribbons. 
MD simulations demonstrated that the variations in packing for the peptides result from 
differences between electrostatic and hydrophobic interactions, while variations in 
twisting result from differences between intra- and inter-β-sheet interactions. In another 






peptides by adding a pair of Glu and Asn residues to either the N-terminus or C-
terminus of a helical, lytic peptide to generate the peptides EN 
(ENFLGALFKALSKLL) and NE (FLGALFKALSKLLNE)75. The addition of the 
residues changed the distribution of polar and non-polar residues of the peptide, without 
disrupting the helical secondary structure. TEM and AFM showed EN assembled into 
long, twisting nanofibrils, whereas NE formed nanomicelles75. The different 
nanostructures led to differences in biological activity; EN had the desired higher level 
of cytotoxicity compared to NE, though NE exhibited high stability in serum. As these 
examples illustrate, controlling the interactions of residues and molecular packing 
controls the self-assembly of the nanostructures derived from the peptides. By 
designing for self-assembly into specific nanostructures, the bioactivity and stability 
can be modulated, making self-assembly a powerful characteristic for designing 
improved peptides. 
 
2.3.3 Reduced aggregation 
 
Aggregation represents a significant limitation to the overall promise of peptide 
therapeutics as the formation of aggregates can limit their potency and lead to 
immunogenicity82, 83. Aggregates can be disordered globules or they can be highly 






assembled structures, we distinguish aggregation processes as those being undesired 
for the peptide of interest.  
 In most cases, a combination of driving forces is responsible for a given 
peptide’s propensity to aggregate, making the task of addressing aggregation difficult. 
As a result, the influence of a given driving force and the key residues promoting 
aggregation in a given peptide should be identified to enable engineering to reduce 
aggregation. One way of accomplishing this is through single-mutation screening, 
which involves rationally designing mutations and calculating the influence of a given 
mutation on a peptide’s propensity to aggregate through a weighted sum of the 
mutation’s contribution to the peptide’s hydrophobicity, net charge, and tendency of 
the peptide to form either α-helical or β-sheet structures82, 85. Select mutants are then 
validated experimentally, and the process is repeated. To address aggregation, protein 
engineering approaches can then be used to mitigate well-known aggregation driving 
forces, namely nonspecific interactions between hydrophobic regions, complementary 
charged regions, or aromatic ᴨ-ᴨ stacking.  
 Hydrophobicity is a critical property to consider when designing for reduced 
aggregation of peptides. Chiti et al. applied single-mutation screening to a series of 
medically relevant peptides, including amylin, ɑ-synuclein, β(Aβ), tau, a human prion 
peptide, and leucine-rich peptides, all of which were observed to form amyloid 
aggregates85. From these experiments, it was concluded that structured, amyloid 
fibrillization could be best avoided with an A76E modification for α-synuclein and an 






β-sheet character that promoted nonspecific association85. Conversely, aggregation 
could be encouraged by increasing the hydrophobicity and β-sheet character, as was 
observed for both H111A and A117V modifications for human prion peptide85. Fowler 
et al. used a similar model to analyze hCT (residues 10-21), a polypeptide hormone 
involved in calcium regulation and bone dynamics that also forms amyloid fibrils in 
solution82. Based on information from the model, I27T and V29S mutations were 
incorporated into hCT to disrupt hydrophobic regions, and these modifications 
contributed to a significant reduction in aggregation82.  
 In addition to the hydrophobic effect, intermolecular salt bridges formed 
between exposed, complementary charged regions represent another significant driving 
force for the aggregation of therapeutic peptides. Chiti et al. showed that salt bridges 
also contribute to the aggregation of leucine-rich peptides and tau and mitigated the 
aggregation using a D24Q mutation in leucine-rich peptides and an R5L mutation in 
tau to eliminate undesirable intermolecular salt bridges85. Similarly, this was 
demonstrated in a de novo ɑ-helical peptide composed of (AEEEXXX)n repeats (X = 
K or R)60. The peptide was designed for improved thermostability by careful pairing of 
either Lys or Arg with Glu to stabilize the helix; however, the increased prevalence of 
Arg residues produced undesirable salt bridges that instead promoted aggregation60, 
likely into amorphous aggregates. The aggregation was attributed to the respectively 
short salt-bridge lifetime of the Glu-Arg pairing and the presence of the additional 
terminal guanidinium group in Arg that encourages salt-bridge formation, but not 






highlighting the importance of considering the overall context of residues in peptide 
design.  
 A third contributing factor that may be related to aggregation is nonspecific ᴨ-
ᴨ interactions, which rely on the spatial overlay of aromatic side chains commonly 
observed with Phe, Tyr, and Trp residues. The effect was observed by Federix et al. 
both through an MD simulation of all 8,000 possible natural tri-peptides with aromatic 
side chains and experimental comparison of the peptides with the highest propensity to 
aggregate in water77. The tri-peptide VFF exhibited the highest propensity to aggregate 
over other hydrophobic combinations77. Although not focused specifically on peptides, 
a computational study by Hou et al. supports these observations86. The study performed 
analysis of solubility and structures of E. coli proteins to identify the role of molecular 
interactions in solubility and identified ᴨ-ᴨ and other ᴨ-interactions as interactions that 
promote aggregation. The biophysical explanation for the aggregation is not clear, and, 
while a number of studies have shown that substitution of aromatic residues, especially 
Phe, reduces aggregation (for example, see references87-90), other work suggests that 
the aggregation affects presumed to be due to ᴨ-ᴨ interactions may actually be related 
to hydrophobic interactions. For example, in amyloid β (Aβ) peptide, mutations of both 
F19 and F20 to either Leu or Ile have a negligible effect on preventing amyloid fibril 
formation91, and the role of the Phe residues is more likely due to hydrophobic effects92. 
With this in mind, attempts to design peptides to prevent aggregation potentially related 
to ᴨ-ᴨ stacking should consider that hydrophobicity of aromatic residues may be more 







2.3.4 Proteolytic stability 
 
Proteolytic stability is a historically significant limitation for therapeutic peptides, as 
the potency of peptides is closely tied to the integrity of their sequence. Susceptibility 
to proteolytic degradation continues to be a concern for the development of therapeutic 
peptides due to the host of proteases encountered in vivo, including digestive tract 
enzymes93-98 and microbial proteases from both commensal and pathogen species97-100. 
 Peptides can be engineered to reduce the degradation associated with the most 
likely encountered proteases and retain the peptide’s function. Increasing proteolytic 
stability is most frequently accomplished by identifying residue specificity of the 
relevant proteases and determining residue substitutions that can avoid degradation. 
Our discussion focuses on linear peptides with canonical amino acids, though 
proteolytic stability can also be improved through cyclization9, 101 and incorporation of 
non-canonical amino acid side chains or backbones9, 102. To identify the residue 
specificity of a protease, peptide mapping can be used. This involves the incubation of 
the peptide substrate with the protease or biological fluids of interest and analysis of 
the resulting fragments to identify preferential sites of degradation. For example, 
McGlinchey and Lee used this strategy to elucidate the role of different cysteine 
cathepsins in the degradation of α-synuclein, a peptide associated with Parkinson’s 






in the soluble and lysosomal membrane-bound forms, while CstD was only capable of 
degrading the peptide while bound to the membrane103.  
 Once the preferred degradation sequences for relevant enzymes are known, 
rational design can be used to reduce susceptibility to degradation. For example, 
histatin 5, a salivary peptide with antifungal potency for Candida albicans104 was 
engineered for improved proteolytic stability in the presence of secreted aspartic 
proteases (Sap2 and Sap9) produced by the fungus. The enzymes preferentially degrade 
histatin 5 at Arg residues, especially K17, and substitution of this residue to either Leu 
or Arg resulted in higher stability104. In another example, the incorporation of Trp at 
four residues of the antimicrobial peptide cecropin A-melittin resulted in significantly 
improved stability in the presence of digestive tract enzymes by improving its helical 
structure and avoiding protease recognition95. Additionally, several synthetic 
antimicrobial peptides were designed based on repeats of the motif (XYPX), where X 
= I, L, or V and Y = R or K, which was designed to resist degradation by trypsin and 
chymotrypsin105. The peptide (IRPR)7 showed strong resistance to both enzymes, while 
also having strong antibacterial activity. In addition to illustrating design for proteolytic 
stability, these examples also highlight the important link between proteolytic stability 
and biological activity. 
 When the specific sequences susceptible to proteolysis are not known, directed 
evolution can be used to improve proteolytic stability. For example, Howell et al. 
started with a cyclized 10-amino acid peptide library previously enriched for binding 






stability in the presence of chymotrypsin while maintaining binding to Gαi1106. After 
production and cyclization of the peptide library as a fusion to mRNA, the library was 
incubated with chymotrypsin and then screened again for binding to Gαi1. The 
screening isolated cyclic peptides with half-lives in the presence of chymotrypsin 
improved by 35-fold compared to peptides isolated without the chymotrypsin selective 
pressure. Even more impressive, the half-lives of the linear versions of the peptides 
were improved 200-fold, and the amino acid sequence, not cyclization, had the stronger 
effect on improving proteolytic stability106. Although this study performed screening 
on cyclic peptides, the results suggest that similar approaches with linear peptides 
would also be successful. Sieber et al. developed another strategy that uses phage 
display to engineer protease-resistant proteins, which would be amenable to 
engineering peptides107. The method places the protein to be stabilized between the C2 
and N2/N1 domains of the gene-3-protein (g3p) of phage and subjects the resulting 
construct to proteolytic degradation. The N1 domain is required for infectivity of the 
phage, so only phage displaying variants that resist degradation and, thus, maintain an 
intact N1 domain can be propagated in bacteria. The method successfully identified 
chymotrypsin-resistant variants of ribonuclease T1 from a large library107. As these 
examples illustrate, both in vitro and in vivo display techniques have the potential to 









2.3.5 Binding affinity and specificity 
 
While interactions of peptides with other biomolecules can be undesirable in the 
context of proteolytic degradation, interactions are highly desirable in other 
applications, including inhibiting protein function78, detecting disease13,76,78, and 
activating or modulating the immune system77. Selective targeting or activation of 
biological pathways with peptides requires considering the myriad of interactions 
possible in vivo. The identification and optimization of peptide sequences that interact 
specifically with desired biomolecular targets are critical aspects of developing 
peptide-based therapeutics.  
 Directed evolution is a powerful approach to engineering peptides for specific 
binding interactions, as it can both produce peptides with higher binding affinity and 
specificity for a selected target and identify recurring motifs of interest that could prove 
useful for rational design approaches. Because of this, directed evolution methods are 
commonly employed to elucidate key factors in peptide binding interactions. Jiang and 
Boder used yeast display to determine the side-chain specificity of the peptide FLU for 
a class II major histocompatibility complex (MHC-II) protein, which is responsible for 
CD4+ T-cell stimulation in adaptive immune response108. FLU was expressed as a 
fusion to the native yeast protein Aga2 to target it to the yeast surface. Simultaneously, 
MHC-II was also expressed, and the interrogation of the peptide by MHC-II occurred 
in the endoplasmic reticulum (ER). If the peptide was recognized and bound by MHC-






display, while a lack of interaction prevented MHC-II from being displayed108. Using 
this method, the authors revealed the preference in the FLU peptide of an aromatic 
residue followed by small hydrophobic residues for association with the MHC-II108. 
Similarly, Lamla and Erdmann used ribosome display to identify peptides that bind to 
the protein streptavidin by fusing a randomized library of 15-amino acid peptides to 
the N-terminus of a carrier protein (bovine heart fatty acid-binding protein, FABP). 
After isolating peptides with dissociation constants as low as 4 nmol/L, a substitution 
analysis of the best peptide revealed the motifs important for binding to allow 
truncation of the 15-amino acid peptide to a 9-amino acid peptide with little loss in 
binding19. When performing directed evolution to engineer peptides with high affinity 
for therapeutic targets, the screen must be carefully considered to generate the desired 
binding and specificity, as the screening procedure influences the resulting binding 
specificity. For example, in a study that targeted M2 macrophages, which assist in 
disease proliferation in cancer, the peptide M2pep was evolved to preferentially target 
M2 macrophages over M1 macrophages by alternating screening steps designed to 
select peptides that bound to M2 macrophages and screens designed to remove peptides 
that bound to M1 macrophages109. This resulted in a 3.8-fold increase in M2pep’s 
relative binding affinity for M2:M1 macrophages109. Additionally, Leal et al. used 
phage display to screen for peptides with high diffusive transport through a cystic 
fibrosis mucus model, and identified peptides with lower affinity for the mucin 
glycoproteins that are the major protein component of mucus110. The peptides have 






mucins to facilitate transport. These examples demonstrate how directed evolution can 
be used to generate peptides with high affinity and specificity when detailed structure-
function information is not available.  
 Computational tools can be used in conjunction with directed evolution to better 
understand the structure-function relationships for binding of variants isolated from 
peptide libraries. One example of combining directed evolution techniques with 
computational analysis is SORTCERY, which uses a combination of yeast surface 
display, FACS, and deep-sequencing to collect data to model the binding landscape for 
a given interaction111. An enhanced version of SORTCERY that relates FACS signals 
to binding energies was used to understand the binding landscape and identify de novo 
peptides with specific affinity for only one of three Bcl-2 peptides (Bcl-xL, Mcl-1, and 
Bfl-1) associated with regulating apoptosis in B-cell lymphoma18. Interestingly, this 
method was also capable of generating peptides that bind specifically to two of three 
targets (but not to the third), highlighting the strength of using a computational 
approach to analyze the data available for individual library members in a directed 
evolution experiment18. Employing computational tools to analyze the large sets of data 
from directed evolution experiments will ultimately improve the ability to apply 
rational design principles to de novo design of peptides with specific binding properties.  
 Directed evolution is useful to improve the binding affinity of peptides when 
the interaction of the peptide with the target is not well understood, but rational design 
can be a more effective tool when sufficient information on the binding target and 






the utility of rational design by perfecting the β-strand amphiphilicity of the 
antimicrobial peptide SB056112. The order of the N-terminal WK residues was 
interchanged to KW, resulting in the N-terminal amine and all cationic residues 
extending in the same direction. The mutation increased by 3- to 4-fold the binding 
affinity of SB056 for model cell membranes composed of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), a zwitterionic phosphatidylcholine, and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol (POPG), an anionic 
phospholipid. Additionally, the mutation increased cytotoxicity toward both gram-
negative and gram-positive bacteria significantly112. The relatively small size of many 
peptides makes rational design strategies like the one used in this example very 
appealing for engineering binding interactions, though the knowledge of the relevant 
interactions with the target must first be elucidated. 
 
2.4 Perspective on future directions for peptide engineering 
 
Biophysical properties and interactions of peptides play an important role in the 
biological function of the peptides and in their suitability for therapeutic applications. 
The long-term goal in therapeutic peptide design and engineering is to reach a point 
where we can simply specify the desired biological function and biophysical 
characteristics of a peptide and identify a de novo peptide sequence to meet the design 






“peptide vending machine”, where the user would simply input the desired biological 
function and biophysical characteristics of a peptide, and a peptide that suits the 
application could be immediately synthesized (Figure 2.3). For example, the desired 
levels of binding to specific targets, as well as the necessary protease resistance, could 
be defined, and computational algorithms would identify the best sequence for the 
application. To reach this point, a continued improvement of structure-function 
relationships for a broad range of peptide characteristics, including both biophysical 
properties and biological function, is needed. While rational design, including 
computational methods, can provide improved understanding on a small scale, directed 
evolution offers the opportunity to explore a much larger region of sequence space 
while also improving peptide design. However, although directed evolution has been 
widely used for designing peptides for targeted binding interactions, the application of 
high-throughput directed evolution tools to address other biophysical characteristics 
has been limited. Developing new strategies for directed evolution and applying 
available methods to peptide engineering will result in improved peptides and provide 
information to incorporate into future rational design and computational approaches. 
As new methods are developed and applied, taking advantage of high-throughput 
sequencing techniques to evaluate the sequences that do not lead to biophysical or 
biological improvements, in addition to those that do lead to improvements, will 
provide a broader understanding of relevant structure-function relationships. 
Incorporation of these “negative” data into structure-function datasets will also 






play an increasing role in peptide design. Ultimately, improvements in both 
experimental techniques and computational tools will combine to push towards the 




2.5 Design strategies pertaining to present study 
 
Membrane penetration, the ability for a species to translocate into the cell through 
endocytosis or non-endocytosis mechanisms, is a key feature that is crucial for the 
therapeutic efficacy of antibacterial, antifungal and other cell penetrating peptides. 
Figure 2.3. The long-term goal of peptide engineering is to enable on-demand, de novo design of a 
peptide to suit any therapeutic purpose. By simply specifying the desired biological function, along 
with the associated biophysical characteristics needed to achieve or maintain this function, an 
appropriate design for this peptide could be obtained without the need to perform experiments 






Defined by their inherent transport capability, these classes of peptides continue to be 
highly explored as delivery systems for poorly internalized and low-bioavailable 
drugs113, 114. Additionally, this biophysical property makes them promising novel 
therapeutics for the treatment of bacterial and fungal pathogens with established 
antibiotic-resistance115. However, the therapeutic potential of these peptides is limited 
by their selectivity113, 114. To mitigate this issue, rational design approaches have found 
the optimized use of the peptide’s cationic and hydrophobic residues to impart the most 
beneficial results.   
Cationic amino acids are thought to contribute to the penetration of cell 
penetrating peptides through electrostatic interactions with negatively charged 
phospholipid head groups and other anionic and hydrogen-bond accepting moieties in 
the plasma membrane116. Using this knowledge, the selection of cationic amino acids 
at key positions has been shown to significantly improve its selective translocation 
utilizing the diversity in the membrane composition of diverse species. This has been 
demonstrated through the rational design of the CPPs, penetratin and Tat (48-60), in 
which arginine was demonstrated to exhibit preferential translation into PC-12 tumor 
cells over lysine at the same positions117. Similarly, alteration of arginine and lysine at 
key positions of LL-37 has been shown to improve the selective penetration of  
S. aureus over E. coli118. Furthermore, other viable approaches to improve translocation 
includes increasing the net charge119 and the number of residue repeats120 in the peptide. 
Consequently, cationic residues are crucial for the association and penetration of 






Likewise, hydrophobic interactions with the cell membrane represent an 
important driving force for translocation as well. This is primarily mediated by the 
interaction of the hydrophobic domains of the peptide with the membrane lipids and 
hydrophobic core of the bilayer, driving their insertion57. With this in mind, the 
segregation of hydrophobic motifs and the orientation, the peptide adopts in relation to 
the surface can be key for their adsorption. Molecular dynamics simulations have been 
very helpful in this regard and have shown that cell-penetrating peptides preferentially 
associate with the membrane utilizing a parallel orientation121, 122 and then become 
perpendicular before insertion122, allowing the hydrophobic domains to pull it through. 
With this in mind, improving the hydrophobic moment has been shown to be an 
effective approach to engineering amphiphilic CPPs123.  
However, increasing the hydrophobic moment may not always help in 
improving translocation. Instead, strategies to find the right balance between 
hydrophobic and hydrophilic residues have been shown to be more beneficial124. 
However, if amphiphilic, then increasing hydrophobic moment has been shown to be 
useful. With this in mind, Chapter 4 of this thesis, builds on these design approaches 
and we have rationally designed our peptides. We have outlined possible mutations in 
our CPPs to enhance translocation into Candida. The future work section in the same 
chapter will provide further design strategies to enhance translocation and CPP-









The protein engineering design strategies will help us design better CPPs which can 
then efficiently carry biomolecular cargoes across the cell membrane barrier and can 
associate with cargoes in covalent or noncovalent ways. Depending on sequences, 
length, and interaction with cargo, the cellular entry may vary. A diversity of chemical 
and molecular methods has been summarized that can help design better peptides as 
therapeutics and delivery vectors. As studies on CPPs continue to improve our 
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Chapter 3: Translocation of CPP-cargo protein fusions into 
Candida albicans cells  
 
Fungal infections caused by the opportunistic pathogen Candida albicans can cause 
complications in immunocompromised patients, and growing drug resistance has 
contributed to a need for novel therapeutic approaches. To help develop new 
approaches, we are studying cell-penetrating peptides (CPPs), which have the ability 
to cross cell membranes and carry biomolecules along with them. We fused the CPPs 
histatin 5 (Hst5) and MPG to green fluorescent protein (GFP) and optimized expression 
conditions to improve yields. We next investigated the intracellular delivery of purified 
Hst5-GFP and MPG-GFP into C. albicans compared to purified GFP with no CPP. 
Translocation of GFP into C. albicans cells was significantly higher when fused to 
MPG (around 40% of total cells), though Hst5 (around 5%) did not improve 
translocation. Molecular dynamics simulations were done in collaboration with Dr. 
Jeffery Klauda’s lab to explain the important findings of experiments and the 
mechanisms employed by the CPPs to enter cells. The simulations show the utility of 
comparing the sequences and structures of each peptide and how their differences can 









C. albicans (Figure 3.1), an opportunistic 
fungal pathogen, causes infections that are a 
reason for concern for 
immunocompromised patients. The 
pathogen can cause cutaneous and mucosal 
infections and systemic diseases1. Infection 
due to C. albicans can be fatal, and drug 
resistance has contributed to ineffectual 
treatment1, 2. Though current treatments exist the drugs can lead to toxicity5 or cells are 
resistant to drugs6. In fact, in the year 2013, Centers for disease control and prevention 
(CDC) listed fluconazole-resistant Candida as a reason for concern6. Therefore, we 
need alternate treatments that specifically target and deliver biomolecular cargo into 
the fungal cells to treat infections caused by C. albicans. An essential feature of an 
effective therapeutic molecule is the ability to successfully deliver across cell 
membranes to intracellular targets. Thus, we propose the use CPPs. As mentioned in 
Chapter 1, CPPs are often amphipathic and cationic peptides and have the ability to 
carry biomolecular cargo into cells7, 8,9-11. We will use the CPPs, MPG and Histatin 5, 
to deliver our fluorescent protein cargo, GFP into the fungal cells. Both MPG and Hst-
5 have previously shown delivery of cargo into cells12-15 (Table 3.1). For example, Hst5 
Figure 3.1. Yeast form of Candida 









has been shown to carry N-terminal fluorescein isothiocyanate (FITC) into cells14, and 
MPG has delivered SiRNA into mammalian cells13. 
 
Table 3.1. CPPs used in the present study 
 





















*Includes charge due to amino acid side chains 
  
 MPG is a short amphipathic peptide that comprises the following domains: (1) 
N-terminal hydrophobic motif which is a derivative of the fusion sequence of the HIV 
glycoprotein 41 and is essential for effective targeting to the cell membrane and cellular 
uptake, (2) a hydrophilic lysine-rich domain which results from the nuclear localization 
sequence of SV40 (simian virus 40) large T-antigen (KKKRKV) and is critical for 
interaction with nucleic acids and cellular uptake, intracellular trafficking of cargo and 
solubility of the peptide, and (3) a linker domain (WSQP) between the two other 
domains, which contains a proline residue to increase flexibility and the integrity of 
both the hydrophobic and hydrophilic domains16, 18, 19. MPG (either bound to or free of 
cargo), has been shown to strongly interact with membrane lipids, and it spontaneously 






dichroism (CD) and Fourier-transform infrared spectroscopy (FTIR) measurements of 
MPG show that it adopts a random coil conformation in water and changes its 
conformation to β-sheet upon interacting with phospholipid vesicles made of a 
dioleoylphosphatidylcholine (DOPC) or dioleoylphosphatidylglycerol (DOPG) 
bilayer. The insertion of MPG-bcl-2 oligonucleotide structure into membrane involves 
a pore like structure upon formation of β-barrel type structure20. In this study, partial 
folding of the carrier peptide into β-sheet structure was observed on interaction with 
the cargo and on linking with the cargo, a distinct β-sheet folding was seen to be 
induced by the phospholipids. 
 Histatins, are histidine-rich peptides, and are secreted by the parotid and 
submandibular glands. Histatins have both antifungal activity against C. albicans21, 22 
and bactericidal effects23. The killing process includes the binding of the peptide to the 
cell membrane of C. albicans followed by transport into the cytoplasm. After the entry 
into the cytoplasm, targeting the mitochondria leads to membrane damage and cell 
death14, 24-26. To exert its fungicidal activity, Hst5 must cross the cell membrane, which 
is unlike many other antimicrobial peptides, where just membrane disruption is 
enough14, 22-27. This action makes Hst5 act like a CPP. 
 Translocation of CPPs through a membrane depends on a number of aspects. 
These include the specific sequences of the CPP, the concentration of CPP and the cell-
type28. Additionally, the cargo that is fused to the CPP and the placement of the cargo 
and CPP in a CPP-cargo fusion may influence the method of translocation29. The 






also shown to depend on its sequence and thus most likely on its conformation20, 30. In 
a recent study, short arginine-rich peptide sequences have shown efficient intracellular 
import properties31. Peptides derived from the HIV Tat protein and the Antennapedia 
homeodomain (Antp) are examples of import sequences31, 32. The cargo has an 
additional role to play on distribution of the conjugate, as shown by PNA-Tat 
conjugates which were located largely isolated in endocytic vesicles33. Efficient cargo 
uptake is necessary in CPP-mediated therapeutics to deliver diverse cargoes by using 
various mechanisms to go through the cell’s membranes34.  
 
3.2 Methods and materials 
 
3.2.1 Construction of plasmids 
 
Expression plasmid for Hst5-GFP was created using pET-21(a) (Novagen, Madison, 
WI, USA). This plasmid has a C-terminal 6XHis tag. A GST fusion partner was 
amplified from pET-42(a) (Novagen) using the primers BamHI-GST-F and GST-
EcoRI-R and introduced into pET-21(a) between the BamHI and EcoRI sites. This 
resulted in the pNGST plasmid (Figure 3.2). Expression plasmids for GFP and MPG-

































Figure 3.2. Plasmid map of pNGST. The pNGST plasmid was created with pET-21(a) as the 
backbone. GST from the pET-42a vectors was added on the N-terminus to help enhance expression 
followed by the cut sites for the insertion of the peptides (EcorI and SacI) and the cargoes (SacI and 
NotI). 6XHis tag is also displayed which has been included in the plasmid design for immobilized 





































Xa-SynB-top-2 GGTTCTCCACTTCCACGGGCCGTGAGCT 4 























































3.2.2 Construction of CPP-cargo protein fusion constructs 
 
The peptides (MPG and Hst5) were introduced into the pNGST plasmid for expression 
by using pairs of annealed oligonucleotides that were commercially manufactured 
(IDT, Skokie, IL, USA). These pairs of oligonucleotides comprised the coding 
sequence for the CPPs, and the coding sequence for a Factor Xa proteolytic cleavage 
site (ATTGAGGGACGC). The Factor Xa site was introduced to allow the removal of 
GST in downstream studies (for constructs that contained GST). Oligonucleotide pairs 
were annealed to form double-stranded DNA inserts to code for the CPPs and Factor 
Xa cleavage site with EcoRI and SacI sticky ends for incorporation into pNGST. As an 
example, the oligonucleotide pairs EcoRI-FactorXa-Hst5-Top1 and EcoRI-FactorXa-
Hst5-Bottom1 and the pairs SacI-G4S-Hst5-Top2 and SacI-G4S-Hst5-Bottom2 were 
annealed to form the two dimers that joined to encode for Hst5. These dimers were then 
introduced between the EcoRI and SacI sites of pNGST (Figure 3.2). 
 DNA encoding the cargo GFP was PCR-amplified from template plasmids in 
our laboratory stocks using the oligonucleotides SacI-GFP-F and GFP-NotI-R. The 
resultant yields were introduced between the SacI and NotI sites of pNGST. 









3.2.3 Bacterial strains and protein expression conditions 
 
Subsequent to plasmid construction, all plasmids were transformed into E. coli DH5α 
(Novagen) cells and sequenced. After successful plasmid construction, the plasmids 
were transformed into E. coli BL21 (DE3; Novagen) for protein expression.  
Overnight culture of 20 mL for each fusion construct was subcultured into  
1000 mL of fresh Luria-Bertani broth (10 mg/mL tryptone, 5 mg/mL yeast extract, and 
5 mg/mL NaCl) with ampicillin (100 µg/ml) at an optical density of OD600 = 0.05 and 
was grown at 37 °C for 2.5 h. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added to each culture aliquot at a final concentration of 0.1 mM to induce the expression 
of the fusion proteins. The constructs were then incubated at 37 °C for 6 h. 
 
3.2.4 Protein extraction and purification  
 
GFP and CPP-GFP were purified to study translocation into C. albicans. The constructs 
were expressed in E. coli BL21 (DE3) cells at 37 °C for 6 h as they were good 
conditions of expression of constructs in E. coli4. The cells were harvested by 
centrifugation and the cells were further lysed using a homogenizer cell disruption 
system (Avestin). Lysates were pelleted by centrifugation and the supernatants 
containing soluble fraction of the cell lysates were collected and passed through a  






cleavage site between the GST and the Hst5, so Factor Xa was used to remove GST 
(Figure 3.4). Following GST removal, the sample was applied to a Profinity Nickel-
nitrilotriacetic acid (Ni-NTA) resin column (Bio-Rad) and was eluted using 20 mM 
sodium phosphate (pH 7.4), 0.5 M potassium chloride, and 500 mM imidazole. Soluble 
lysate, flow-through, washes and elutes were collected to further run a gel. Coomassie 
stain was used to estimate the purity of the proteins. MPG-GFP (96 % purity) and GFP 
were purified using IMAC, similar to Hst5-GFP (90%) using an IMAC column. Both 
MPG-GFP and GFP lacked a GST on the N-terminus as they were well expressed even 
without a soluble partner. 
 
3.2.5 Quantification of translocation into C. albicans 
 
Translocation of the protein fusions into C. albicans cells was measured using flow 
cytometry. For each sample, 100 μl of protein solution (200 μM) was made in 10 mM 
sodium phosphate buffer and mixed with 100 μl of C. albicans cell suspension 
containing 5 × 105 cells (in 10 mM sodium phosphate buffer). The cells and fusions 
were incubated at 30 °C for 1 - 72 h, depending on the experiment. Cells were pelleted 
by centrifugation at 5,000 x g for 10 min at 4 °C. The cell pellet was then washed with 
10 mM sodium phosphate buffer and again pelleted at 5,000 x g for 10 min at 4 °C. 
The cell pellet was further resuspended in 200 μl of 0.025% (wt/vol) trypsin 






proteins36. Following trypsin treatment, cells were washed with sodium phosphate 
buffer and pelleted, and then resuspended in 250 μl of 10 mM phosphate buffer to 
analyze by flow cytometry. To examine the effect of fusions on the C. albicans cells, 
propidium iodide (PI, 1 mg/ml; Invitrogen) was added at 0.2 mg/ml to each sample 
immediately before flow cytometry. Cell suspensions were studied for GFP and PI 
fluorescence using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, 
CA). Single cells were chosen for analysis, and the data was analyzed using the FlowJo 
software (FlowJo, LLC, Ashland, OR). Three separate biological replicates (three sets 
of each protein from different sources with three different C. albicans cell cultures) 
were used to perform the experiments. was completed using GraphPad Prism (La Jolla, 
GA, USA). A two-way ANOVA (α = 0.05) followed by Tukey’s multiple comparisons 
test was conducted to compare between different constructs (Figure 3.6, 3.7), and the 
significance of incubation time and on the translocation of various constructs. 
Summaries of the statistical analyses are provided in the appendices (Appendix A, 
Table A2 – A4). A p-value of p < .05 was considered significant, and the level of 
significance is indicated in the tables by the number of asterisks (ns for not significant, 








3.2.6 Measurement of relative fluorescence unit (RFU) using a 
fluorescent plate reader 
 
GFP, MPG-GFP and Hst5-GFP were purified using a Ni-NTA profinity immobilized 
metal affinity column by procedure listed in Section 3.2.4 and then concentrated to  
200 μM. 110 μl of 200 μM protein samples were loaded a 96-well plate (Corning, NY, 
USA) and the samples were thoroughly mixed. Serial dilutions (10-fold) were done to 
get a range of concentrations from 200 μM to 0.02 μM. RFU was measured on 
SpectraMax M2 plate reader (Molecular Devices, CA, USA) to compare between the 
proteins. The fluorescence in each well was measured for a wavelength range from 450 
nm to 600 nm and the analysis was done at room temperature. Statistical analysis was 
done using GraphPad Prism (La Jolla, GA, USA). A two-way ANOVA (α = 0.05) 
followed by Tukey’s multiple comparisons test was conducted to compare between 
different constructs. Summaries of the statistical analyses are provided in Appendix A, 
Table A1. A p-value of p < .05 was considered significant, and the level of significance 
is indicated in the tables by the number of asterisks (ns for not significant, * for p < .05, 









3.2.7 Circular dichroism to study secondary structure of protein fusions 
 
CD spectra were collected for GFP, MPG-GFP and Hst5-GFP at room temperature 
using a micro-cuvette quartz cell with a 10 mm path length (Fisher Scientific). The CD 
spectrometer J-810 (Jasco) was set to scanning mode with a 195-300 nm range, 50 
nm/min scanning speed, 1 nm bandwidth, and 1.0 nm data pitch. For proteins in 
solutions, the measurement was performed with 400 µL of 0.5 µM proteins solution in 
Na2HPO4 buffer. The signal was converted to molar ellipticity [𝜃] using 
[𝜃] = !""×$
%×&
        (Equation 4.1) 
where, 𝜃 is the ellipticity in degrees, 𝐶 is the molar concentration, and 𝑙 is the quartz 
cell pathlength. 
 
3.2.8 Simulation method to study translocation of peptides 
 
The membrane was modeled by Jeffery Klauda and Mahdi Ghorbani with the highly 
mobile membrane-mimetic3 (HMMM) model. This model had its membrane core was 
replaced with an organic solvent and short tailed lipids were used as headgroups. This 
was done to enhance the lipid dynamics while conserving atomistic detail of protein-
lipid interaction. In HMMM model, a lipid area scaling factor of 1.2 was used along 
with a 6-carbon lipid chain model. Temperature was set at 298K. This system closely 






consists of 150 lipid per leaflet. Each study was run for 300ns using NAMD with a time 
step of 2 fs. After 300ns the CHARMM server was used to translate the HMMM model 
to a full membrane model and the simulation was run for additional 100ns. 
 








Lipids per leaflet 150 
 
3.3 Results and discussion 
 
We produced CPP-cargo fusions (Figure 3.3) recombinantly in E. coli. The genetic 
fusions of CPPs to protein cargoes were linked covalently via a flexible glycine serine 
linker4, 35. Glutathione S-transferase (GST), a soluble partner, was added to the N-
terminus of the construct to enhance production37, 38. A Factor Xa cleavage 
(ATTGAGGGACGC) site was added between the soluble partner and the CPP. This 
cleavage site would allow for the removal of GST before purification. We evaluated 
the expression of combinations of SynB, Hst5, and their fusions to biotin carboxyl 
carrier protein (BCCP), green fluorescent protein (GFP) and maltose binding protein 
(MBP)4. We observed that both the CPP and the cargo protein affected expression, and 






proteins4. These results allowed improved production of the constructs considered and 
are a promising starting point for the expression of new CPP-cargo fusions. We further 
chose Hst5 and MPG as our CPPs, which have already shown the translocation into 
different cell types. In this study, we used green fluorescent protein (GFP) as our cargo. 
GFP is a protein with 238 amino acid residues (26.9 kDa) that absorbs blue light at 395 
nm and exhibits bright green fluorescence at 509 nm39, 40. The green fluorescence is 
stable and almost no photo bleaching is seen40. This protein has been selected due to 
its fluorescence property, which will help us to study the translocation into cells when 
it is fused to an appropriate CPP. At the same time, since it is bigger in size compared 






Figure 3.3. Representation of GST-CPP-cargo protein fusion construct. CPPs are linked 
to the protein cargos via a G4S peptide linker. GST was included on the N-terminus, as an 
expression partner to improve expression, and a 6XHis tag was incorporated on the C-
terminus for detection of construct expression. A Factor Xa cleavage site was attached 
between GST and CPP to allow for removal of the GST in downstream processes. The 
genetic construct that encodes for the fusion proteins was designed with restriction enzyme 








3.3.1 Detection of fusions inside Candida albicans cells 
 
GFP and CPP-GFP were purified to study translocation into C. albicans. The constructs 
were expressed in E. coli BL21 (DE3) cells at 37 °C for 6 h as they were good 
conditions of expression of constructs in E. coli4. Following cell lysis and extraction of 
the proteins GFP, MPG-GFP and Hst5-GFP were purified using IMAC.  
 
 Subsequent to purification, we studied the intracellular delivery of the purified 
proteins into the fungal pathogen C. albicans. To evaluate the CPPs for translocation 
into Candida species, C. albicans strain SC5314 was incubated with Hst5-GFP, MPG-
GFP and GFP lacking a CPP. We studied and quantified translocation of the proteins 
using flow cytometry (Figure 3.5). Single C. albicans cells were chosen, and the 
Figure 3.4. Purification of GFP, Hst5-GFP and MPG-GFP. CPP fused to GFP and unconjugated 
GFP were expressed in BL21 (DE3) cells at 37 C for 6 h with 0.01 mM IPTG. GST was removed 
prior to purification. Coomassie stain was used to estimate the purity of fusion proteins. Crude 
soluble lysates (L), flowthrough (FT), washes (W1, W2) and elution (E) from immobilized metal 
affinity chromatography are shown. Cleavage with Factor Xa to remove GST from Hst5-GFP 
was done before purification (A). MPG-GFP was purified using IMAC (B). The crude soluble 
lysate contains the whole construct; flow through does not bind to the column and so flows 
through; elutes are obtained using a gradient of 50% imidazole. Molecular weight: GFP = 27 
kDa, Hst5-GFP = 30.1 kDa, MPG-GFP = 30.5 kDa. 
 



















percentage of fluorescence-positive (GFP-positive) cells was used to evaluate the GFP 
delivery efficacy. The protein fusions were incubated with trypsin for different times 
over a range of time points that ranged from 0 mins, 5 mins, 15 mins, 30 mins, 45 mins 








About 40% of the fungal cells exhibited a green fluorescence signal (Figure 3.6, 3.7) 
when treated with a final concentration of 100 μM purified GFP (Figure 3.5 (c)), MPG-
GFP (Figure 3.5 (d)) and Hst5-GFP (Figure 3.5 (e)). (This concentration reflects the 
Figure 3.5. Translocation of proteins. Flow cytometry was used to quantify translocation and 
membrane permeabilization in C. albicans for (a) cells incubated with buffer only and PI, (b) cells 
incubated with methanol (c) cells incubated with GFP and PI, (d) cells incubated with MPG-GFP and 
PI, and (e) cells incubated with Hst5-GFP and PI. The translocation studies were done for multiple 
replicates but a, b, c, d and e are a representative set of data. Only single cells were selected for 
analysis. In each plot, quadrant Q1 represents cell that are PI +/GFP -, Q2 represents those that are PI 
+/GFP +, Q3 represents those that are PI -/GFP +, and Q4 represents those that are PI -/GFP -. The 
numbers under each quadrant label provide the percentage of cells in the experiment that fall into 
each quadrant. The quadrant boundaries were chosen with cells only. Each cell in the sample is 
represented by a dot, and the color on the dot plots indicate the density of cells (red represents high 
density and blue represents low density). 
 
(a) Cells only (c) Cells + GFP 
(e) Cells + Hst5-GFP (d) Cells + MPG-GFP 
(b) Cells + Methanol 





















total protein concentration of the sample and does not take the purity into 
consideration). MPG-GFP showed significantly higher translocation as compared to 
both GFP and Hst5-GFP (p ≤ 0.001 and p ≤ 0.0001, respectively) (Figure 3.7). To 
further investigate the effect of the fusion proteins on C. albicans, we evaluated the 
permeability of the cells using PI. Cells are usually impermeable to PI, but PI 
fluorescence can be found inside cells with destabilized membranes. Destabilization 
can occur either due to cell death or due to pore formation on the membrane41, 42. Our 
results show that there is significantly low, <2% PI-positive cells following incubation 
with MPG-GFP and Hst5-GFP, indicating the fusion protein does not significantly 
affect the membrane integrity. This was analogous to the level of toxicity of GFP alone 








Figure 3.6. Translocation studies data for 1 h – 24 h. Flow cytometry was used to quantify translocation and 
membrane permeabilization in C. albicans. Single C. albicans cells were selected, and the percentage of 
fluorescence-positive cells was used to evaluate the GFP delivery efficacy. The permeability of the cells was 
evaluated after treatment with the fusion protein using propidium iodide (PI). (a) Cells were incubated with 
the fusions for 1 h, 4 h, 18 h and 24 h to select the best incubation time. 24 h showed significantly higher 
translocation compared to the others (b) Propidium iodide uptake for the same times were recorded with no 
significant uptake of PI (c, d) Raw data for each replicate (c) GFP positive and (d) PI positive with no 
methanol, to compare between different  purified samples and their effect on translocation Error bars 











Figures 3.6 (c) and (d) represent the data for each replicate, which shows the 
contribution of a single replicate to translocation. Each replicate represents three 
different batches of purified protein samples which were incubated with three separate 
cell cultures. As seen from Figure 3.6 (c), replicates 1 and 3 behave similarly and show 
>50% GFP positive cells at 24 h whereas replicate 2 has higher translocation at 18 h. 
This points to either an issue with the purified protein in replicate 2 or with the cells 
cultured. From these data we can learn that translocation is heavily dependent on each 
data set and the average of data sets might not always represent the correct measurable 
quantity.  
 
Another fact to consider is the translocation of GFP only. GFP usually does not 
translocate into cells but further studies might be needed to evaluate the reasons for 
translocation of GFP without a CPP. Although trypsin treatment was done to remove 
Figure 3.7. Cellular uptake studies. The flow cytometry data for 24 h incubation samples were 
analyzed further for 7 replicates to quantify the translocation and membrane permeabilization 
in C. albicans. The percentage of fluorescence-positive cells was used to evaluate the GFP 
delivery efficacy. The permeability of the cells was evaluated after treatment with the fusion 
protein using propidium iodide (PI). (a) Translocation data at 24 h for 7 replicates showed 
significantly higher uptake of MPG-GFP compared to both GFP and Hst5-GFP (b) Propidium 
iodide uptake for the same times were recorded with no significant uptake of PI. Error bars 
represent standard error of the mean for 7 replicates for panels (a, b). Refer to Appendix A, 








surface-bound proteins, it might not have been effective in removing all of the GFP and 
alternate approaches can be used for example fluorescence quenching groups43. One 
thing to note for the experiments outlined above is that these were done based on mass 
of sample and differences in purity and fluorescence activity of GFP could affect 
results. 
As discussed previously, MPG enters cells by formation of a pore. This is 
consistent with the results of this study too, where MPG likely delivers GFP by making 
a pore without causing cell death. The pore is repaired, and, thus, we do not detect any 
PI fluorescence, since PI can be detected only when membranes are destabilized due to 
pore formation or cell death.   
 
3.3.2 Fluorescence intensity measurements of purified GFP, MPG-GFP 
and Hst5-GFP 
 
To understand if the difference in translocation of purified proteins is due to the 
fluorescence activity of each fluorescent molecule, we used a fluorescent plate reader 
(SpectraMax M2) to measure the relative fluorescent units of GFP, Hst5-GFP and 








The analysis showed that at the same conditions of mass concentration and 
temperature, the constructs had comparable fluorescence intensity at the lower 
wavelengths. However, at higher wavelengths, for example, 520 nm there was a 
significantly higher fluorescence intensity of GFP as compared to MPG-GFP and Hst5-
GFP (p ≤ 0.0001 and p ≤ 0.01, respectively). GFP has an emission spectrum at 509 nm 
and these results at 520 nm molecules show that effectively GFP molecules are 
fluorescently more active than either MPG-GFP (purity 96%) or Hst5-GFP (purity 
90%) at a concentration of 200 µM. Given that the purities of each protein are different, 
fluorescence activity could be affected. This result in turn can be compared to the 
Figure 3.8. Measurement of relative fluorescence unit (RFU). The fluorescence intensity data for 
200 μM of GFP, MPG-GFP and Hst5-GFP were analyzed to compare between the fluorescence 
activities. (a) Scattered dot plot of representing RFU’s at different wavelengths for GFP, MPG-
GFP and Hst5-GFP. Error bars represent standard error of the mean of 3 biological replicates. 







translocation data presented in Section 3.3.2. The difference in fluorescence activity 
could better explain the limited fluorescence signal observed in flow cytometry (GFP 
positive cells), for MPG-GFP and correlated to the translocation results.  
 
3.3.3 Simulation results to better understand experimental data 
 
To better understand the molecular interactions between the CPPs and the cell 
membrane, Jeffery Klauda and Mahdi Ghorbani to ran multiple simulations on the 
peptides MPG and Hst5 using a HMMM3 model. Simulations included the peptides 
only and not the fusion construct as whole, as we anticipate that any changes in the 
peptide will help to enhance translocation. Also, addition of the cargo would make the 
simulation calculations computationally expensive. The structure of the peptides was 
predicted to be 𝛼-helical in aqueous phase using a peptide structure prediction 
webserver (PEPFOLD3)44. The HMMM model (Figure 3.9) closely mimicked a yeast 







Bias in the system was avoided using three different orientation with respect to 
membrane plane. Each run was for 300ns and we saw the insertion of MPG into the 
membrane after 300ns whereas Hst5 failed to insert into the membrane (Figure 3.10). 
After 300 ns, the distances of each residue were measured from the membrane plane 
(Figure 3.11) to help understand the contribution of each residue to translocation.  
 
 
Figure 3.9. Comparison of full-membrane model and HMMM model. In a HMMM model, 
yellow acyl tails (sticks) of the lipids is substituted by an organic solvent (yellow area in 
HMMM model representation). In this paper, a full DOPS lipid molecule (inset) was 
denoted by a short-tailed DVPS molecule (circled part of the molecule). Red: oxygen atoms, 
Blue: nitrogen, Gold: phosphorus, and Ice blue: carbon (except the C6–C18 in yellow), 
Light blue: bulk water molecules. Figure taken from Ohkubo et al. Accelerating Membrane 
Insertion of Peripheral Proteins with a Novel Membrane Mimetic Model7. Copyright © 








As seen in figure 3.10, MPG enters the membrane through its hydrophobic N-
terminus (blue color representation in heat map in Figure 3.10 (a)) whereas Hst5 fails 
to enter the membrane. The hydrophobic end of MPG helps in insertion, while much 
of the charged residues are farther away from the plane. Our experimental construct 
design has GFP attached to the C-terminus and the simulation results support our 
experimental results which show MPG can deliver a biomolecular cargo, which is fused 
at the peptide’s C-terminus. As mentioned above, MPG probably employs pore 
formation to enter the cell membrane. On the other hand, Hst5 is highly charged and 
has charge distributed all through the sequence. The positively-charged peptide thus 
sticks to the membrane and this electrostatic interaction prevents insertion into the 
MPG at 0 ns MPG at 50 ns MPG at 300 ns 
Hst5 at 0 ns Hst5 at 50 ns Hst5 at 300 ns 
Figure 3.10. Translocation of CPPs using HMMM membrane model at various time points. 
MPG inserts after 300 ns into the membrane whereas Hst5 does not go in even after 300 ns (Data 









These data show that both experiments and simulations can be used in 
collaboration to study the translocation of peptides into membranes. The consistent 
results obtained from both simulation and experiments, show that simulation can be 
used as a useful tool in designing better experiments. We will need further studies to 
use simulations to design better peptides that can enhance translocation. 
 
3.3.4 Secondary structure of proteins 
 
We further wanted to know the contribution of the peptide or the protein on the 
secondary structure. Studies have been done to analyze the structure of CPPs but not 
much is known about structures of peptide-cargo fusions. To explain for this 
Figure 3.11. Insertion of peptides into the model membrane. The distance of each residue 
from the membrane plane was measured. (a) Distance of MPG residues after 300 ns into 
the membrane (b) Distance of Hst5 residues after 300 ns into the membrane (Collaborators: 








complexity, we evaluated the secondary structure of CPP-cargo fusion by using CD 
(Figure 3.12). The baseline CD spectrum for buffer was subtracted from spectra of GFP 
and the CPP-GFP fusions.  
 
We report our results in ellipticity (θ x104 deg-cm2/dmol). Due to substantial 
noise at far-UV range, which could be attributed to high absorbance, we used a lower 
protein concentration of 0.5 µM. Buffer alone spectra was subtracted from each 
spectrum for each peptide. MPG alone has a characteristic random coil structure45 but 
the proteins in this experiment showed a ß-sheet conformation which is characteristic 
of GFP.  
Further experiments with cells will provide knowledge on the conformation of 
fusions when the proteins are combined with the C. albicans cells. Studies of CPP-
membrane interactions with model lipid vesicles and structure information using CD, 
Figure 3.12. CD spectra of CPPs (0.5 µM) in sodium phosphate buffer. GFP (green), MPG-GFP 







fail to consider the complexity of the cell matrix46, 47. Gong et al. evaluated the 
interaction between peptides and C. albicans cells by using CD48. Some peptides 
maintained their structures while others did not for example, peptides like MPG and 
penetratin maintained their random coil structure whereas MAP and cecropin B shifted 
to α-helical structure from random coil. Experiments of protein fusions with Candida 
will provide better knowledge of secondary structure of fusions that can help 
understand translocation. 
 
3.3.5 Design of MPG variants to increase translocation  
 
MPG can deliver biomolecular cargo, GFP into C. albicans with very little killing  
(Section 3.3.1). These results encourage the extension of the study towards residue 
substitutions. For an improved understanding on the behavior of the residues and their 
contribution towards translocation, we collaborated with Dr. Jeffery Klauda and his lab 
and calculated the interaction energy of each residues of native MPG with the 
membrane (Figure 3.13). We calculated the distance of each residue from the top 
membrane plane of the model membrane. The interaction energies helped us to identify 
residues that do not contribute to translocation of the peptide into the membrane, and 
modifying which could help increase translocation. These studies include MPG only 






enhance translocation and presence of the cargo would make the computations 
expensive. 
 
MPG enters the membrane model from its hydrophobic end (Figure 3.13). The 
residues S13 and T14 are both hydrophilic uncharged residues that do not appear to 
contribute to translocation, and we propose to modify them to residues lysine (K) and 
arginine (R), which are charged hydrophilic groups. Inclusion of these residues’ in the 
mid-region will help the attachment of the peptide to the membrane and transport of 
the peptide to the other side. CPPs in general tend to have charges in the mid-region of 
the sequences9, and, thus, altering the mid-region residues to hydrophilic charged 
residues would aid in increasing translocation. Arg and Lys will help preserve the 
hydrophilic nature at the respective sites.  
Charged residues at the C-terminus stick to the membrane and do not enter the 
membrane. Although these charges possibly help attachment of the peptide to the 
Figure 3.13. Interaction energies of MPG (native) residues. Interaction energy (kCal/mol) of 
each residue of MPG from the phosphate plane of a yeast model membrane and the distance (A°) 






membrane, MPG-GFP with GFP attached at the C-terminus of MPG, needs to enter the 
cells. Altering the charged residues to hydrophobic residues is likely to help and 





We are using peptides to design alternate drug delivery systems to translocate cargo 
into the fungal pathogen C. albicans. We were able to study peptides that selectively 
translocated into C. albicans and were able to quantify delivery of a biomolecular 
cargo. The 3-fold increase in translocation with MPG showed promising results and 
moving forward we would like to use the both simulations and experiments to design 
better peptides to enhance translocation. The knowledge gained from this study will 
enable the design of an alternate functional drug delivery vehicle to treat fungal 
infections. These results show that MPG can be used to deliver GFP. We need to 
understand if increasing the concentration of the fusion or modifying the residues of 
the CPPs can improve results. To understand how the peptide-cargo fusions are 
translocated and any intracellular effect of the cargo and the CPP, further studies will 
need to be done. Additionally, we believe similar studies with other CPPs or cargoes 
will help better understand the capabilities and limitations of CPP-cargo fusions in 






studying these altered CPPs and their fusions could help understand translocation and 
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Chapter 4: Design CPP variants for translocation of CPP-cargo 
protein fusions into Candida albicans cells  
 
In the previous chapter, we were successfully able to deliver a biomolecular cargo in  
C. albicans cells. Simulations and experiments were able to help us study and explain 
the translocation mechanism of the peptides. We were further able to use simulations 
as a tool to help design CPPs that could help improve translocation. The utility of using 
interaction energies of the MPG and how each residue contributes to translocation of 
the peptide was examined. In this chapter, MPG variants have been designed and 




In Chapter 3, CPPs were studied that can deliver a protein biomolecular cargo into the 
fungal pathogen, Candida albicans. MPG successfully delivered protein cargo to C. 
albicans, but the levels of translocation could be improved. MPG is a short amphipathic 
peptide that comprises different domains and the separate domains are responsible for 
interaction with nucleic acids and cellular uptake, intracellular trafficking of cargo and 
solubility of the peptide1-3; hydrophobic domain is responsible for membrane anchoring 






necessary to target a subcellular compartment, to increase solubility of the vector and 
for the complex formation with hydrophilic negatively-charged molecules4-6. 
Design of CPPs for improved translocation involves major considerations 
including the interaction of the CPPs with the membrane. Charge and hydrophobicity 
are important properties to consider for improving translocation efficacy of a peptide 
and a mechanistic understanding of translocation using modeling will further help in 
designing peptides. Experimental and simulation studies in the previous chapter, 
showed that MPG enters through the N-terminus and these results provide information 
to help design variants to better understand translocation. To explore the structure–
function relationships of CPPs and their interaction with C. albicans, our lab has 
previously worked with translocation of another peptide, SynB, into C. albicans7. 
Increase in net charge and decrease in hydrophobicity of native SynB, led to designing 
of SynB variants that provided a better understanding of the role of specific properties 
in translocation. The derivatives of SynB, SynB-1, and SynB-2, were designed with 
higher charges, and showed the presence of a higher amount of peptide in the cytosol 
at a lower concentration of peptide. On reducing the hydrophobicity of native SynB, 
SynB-7, there was a reduction in vacuolar lysis, that was consistent with vacuolar 
localization but maintained the energy-dependent endocytosis translocation 
mechanism observed in SynB7. These SynB variants will be interesting to study for 
translocation of biomolecular cargo into Candida as they have not been studied for 






peptide residue substitutions to improve translocation. In this chapter, we will study the 
translocation of GFP with variants of MPG. 
 As has been seen from previous work8-10, charge and hydrophobicity play 
important role in transportation of CPPs into cells. Higher net charge affects cell 
viability significantly more than other properties9-11. Net charge of peptides, in general, 
affects membrane association and could enable the deeper membrane insertion and 
contact of hydrophobic residues11.  
To understand the behavior of the peptide residues and their role in 
translocation, we collaborated with Dr. Jeffery Klauda and his lab and determined the 
interaction energy of each of the residues of the wild-type MPG with the membrane 
and also the distance of each residue from the top membrane plane of a HMMM 
model12 (Figure 3.9).  
To design better CPPs, identifying the mode of action of CPPs and interpreting 
the type of interaction that they have with membrane components for example, the 
phospholipids is important. At the same time, it is essential to identify a peptide’s 
primary and secondary structures. As discussed in Chapter 1, CPPs use three main 
mechanisms to enter the cells - direct penetration, translocation by forming a temporary 
structure and an endocytosis-mediated cell entry. CPPs interact with the plasma 
membrane, mostly by direct electrostatic interactions with the phospholipid headgroups 
in the membrane, but the interactions differ based on the CPP. For example, penetratin 
interacts specifically with negatively charged membranes while transportan does not4, 






membranes with their hydrophobic ends and have been known to form pore-like 
structures by forming a β-barrel structure4, 14, whereas Pep-1 interacts with the 
membrane using an α-helical structure4, 15. SynB, a CPP which is part of the 
antimicrobial peptide (AMP) protegrin 1 (PG-1)16 is known to translocate by energy-
dependent endocytosis mechanisms16, 17. SynB shows a β-sheet structure in a partial 
hydrophobic environment and assumed a more dominant helical conformation in a pure 
hydrophobic environment8. To study the interaction of the peptide and C. albicans, 
circular dichroism was done and the results showed that SynB assumed a β-sheet 
conformation.  
Based on previous work in the Karlsson lab7 and results in Chapter 3,  we 
studied variants of MPG that were rationally designed to enhance translocation. We 
worked on modifying the residues of MPG to try to enhance translocation. CPPs with 
higher net charges tend to enter cells via direct translocation and traffic to the cytosol, 
supported by a close interaction with the membrane. The hydrophobicity does not 
directly affect the translocation efficiency; however, it alters the membrane association 
pattern and affects the translocation mechanisms18. Translocation efficiency depends 
on the sequence, length and location of the positive charges in a sequence14, 16, and thus 
adding Lys or Arg residues can help alter translocation. The guanidinium group in 
arginine can form two hydrogen bonds with phosphate headgroups in the membrane19 
replacement with arginine can help translocation. Hydrophobicity on the other hand 
can be altered by adding aromatic amino acids Trp, Phe and Tyr to peptide sequence. 






give important information on peptide residue interaction with membrane and the 
peptide’s structural and conformational behavior in the presence of lipids. For example, 
Ulmschneider et al. used simulation to study interaction of melittin with a 
phosphatidylcholine (POPC) bilayer and its translocation20. The peptide residues below 
the phosphate head groups adopted a helical conformation while the residues out of the 
bilayer remain unfolded20. 
Simulations studies helped design MPG variants based on interaction energies 
that were calculated using a full membrane model. MPG variants were designed based 
on the charge and hydrophobicity of the peptide (Table 4.1). These variants were 
intended to study if translocation efficiency was changed by the net charge of the 
peptides and in turn the antifungal activity. 
The SynB variants were designed previously in the Karlsson lab7, 18 out of 
which SynB-2 has been shown to have higher translocation and toxicity compared to 
native SynB. On reducing the hydrophobicity of SynB (SynB-7), there was no increase 
in translocation or toxicity. We have chosen these two mutations along with the native 
SynB to compare translocation efficiency. These along with SynB + (combined 
properties of SynB-2 and SynB-7) would provide us with knowledge that could further 
help us in translocation studies. In this chapter, we will study translocation of GFP with 
variants of MPG. This study would provide us with knowledge how fusion of the 
peptides to GFP would affect the translocation and if peptide or cargo has a greater 






 We will produce these fusions recombinantly and purify them to study their 
translocation using experimental and if feasible, will compare our results with 
simulations done in the Klauda Lab. The fusions of these new mutated peptides will be 
compared with the wild-type MPG-GFP and GFP only using analogous techniques 
outlined in Chapter 3. 
 With these new modified CPPs, we expect to see higher translocation of the 
fusions into C. albicans. Issues might arise with production of these fusions as each 
new peptide and cargo fusion expresses differently, though we do have shown 
previously that most constructs express well at a standard temperature and induction 
time.   
 
4.2 Methods for introducing design changes to peptides 
 
4.2.1 Cloning of plasmids 
 
The expression plasmid for or study was constructed using pET-21(a) 
(Novagen, Madison, WI, USA). This plasmid comprises a C-terminal 6XHis tag. The 
oligonucleotides sequences for our constructs are given in Table 4.2.  
 







Peptides were inserted into the pGST(-) plasmid for production by means of pairs of 
annealed oligonucleotides (Table 4.2) that were produced commercially (IDT, Skokie, 
IL, USA). These pairs contained the coding sequence for CPPs. The pairs of 
oligonucleotides were annealed to form double-stranded DNA inserts to code for the 
CPPs with EcoRI and SacI sticky ends for insertion into pGST(-) (Table 4.1). For 
example, the pairs EcoRI-T14K-Top1 and EcoRI-T14K-btm1 and the pairs SacI-
T14K-Top2 and SacI-T14K-btm2 were annealed to form two dimers that combined to 
encode for T14K. These dimers were inserted between the EcoRI and SacI sites of 
pGST(-). 
The DNA encoding the cargo, GFP, was PCR-amplified from a template 
plasmid in our lab stock that used the primers SacI-(Cargo)-F and (Cargo)-NotI-R 
(Table 5.2), where (Cargo) denotes GFP. The subsequent products were introduced 
between the SacI and NotI sites of pGST(-). 
 























































4.2.3 Bacterial strains, expression conditions and purification 
 
Subsequent to plasmid construction, all plasmids were transformed into E. coli DH5α 
(Novagen) and sequenced. Following successful plasmid construction, the plasmids 
were transformed into E. coli BL21 (DE3; Novagen) for expression studies. 25 mL of 
over-night culture for each construct was subcultured into 1000 mL of fresh Luria-
Bertani broth (10 mg/mL tryptone, 5 mg/mL yeast extract, and 5 mg/mL NaCl) at an 
optical density of OD600 = 0.05 and grown at 37°C for 2 h. The fusion protein 






to each culture aliquot at a final concentration of 0.1 mM. The cultures were then 
incubated at 37 °C for 6 h.  
After harvesting the cells by centrifugation, the cells were resuspended in the 
buffer for purification (125 mM Tris, 150 mM NaCl, 1 mM ethylenediaminetetraacetic 
acid (EDTA) (pH 7.5). The cells were then lysed using a homogenizer cell disruption 
system (Avestin). After lysis of each sample, the whole-cell lysates were pelleted by 
centrifugation at 11,419 × g for 50 min at 4 °C, and the supernatants containing the 
soluble fraction of the cell lysates were collected. The soluble fraction of each lysate 
was passed through a 0.45 μm filter and applied to an IMAC Profinity Ni-NTA resin 
column (Bio-Rad). After thoroughly washing the column, the flow-through and washes 
were collected. The proteins were eluted in a buffer containing 20 mM sodium 
phosphate, 0.5 M potassium chloride (KCl), and 500 mM imidazole (pH 7.4). 
 
4.2.4 C. albicans strain and culture conditions 
 
C. albicans strain SC5314 (American Type Culture Collection, Manassas, VA). 
Candida cells were inoculated from yeast-peptone-dextrose (YPD) agar plates (1% w/v 
yeast extract, 2% w/v peptone, 2% w/v glucose, 2% w/v agar) into 5 mL of liquid YPD 
medium (1% w/v yeast extract, 2% w/v peptone, and 2% w/v glucose) and were grown 
at 30 °C and 230 rpm, overnight. The overnight culture was introduced to 5mL of fresh 






grown at 30 °C to OD600 = 0.5 (~ 1x107 CFU/mL) at 225 rpm. Cells were harvested by 
centrifugation at 4,300 × g for 10 min and washed twice with 10 mM sodium phosphate 
(Na2HPO4) buffer to use in downstream assays. 
 
4.2.5 Quantification of translocation into C. albicans 
 
For each protein fusion, 100 µL of solution (100 µM) was prepared in 10 mM Na2HPO4 
buffer, and was mixed with 100 µL of cell suspension containing 5 x 105 cells in 10 
mM Na2HPO4. This mixture was then incubated at 30 °C for 1 h and 24 h. Cells were 
collected by centrifugation at 5000 × g for 10 min at 4 °C and washed once with 10 
mM Na2HPO4. The cell pellets were further incubated with 200 µL of 0.025% trypsin 
(Invitrogen, Waltham, MA) at 37 °C for 30 min to remove surface-bound peptides or 
proteins21. Cells were then collected by centrifugation at 5000 × g for 10 min at 4 °C 
and washed with 10 mM Na2HPO4. Propidium iodide (PI, 1 mg/ml; Invitrogen) was 
added at 0.2 mg/ml right before flow cytometry. Cell suspensions were analyzed for 
GFP and PI fluorescence using a BD FACSCanto II flow cytometer (BD Biosciences, 
San Jose, CA). Only single cells were selected for analysis, and the analysis was 








4.3 Results and discussion 
 
The goal of this study was to produce mutated CPPs and their fusions to cargo, 
recombinantly, and to explore the translocation of the purified CPP-cargo into C. 
albicans and compare their translocation with wild-type CPPs. The CPPs chosen for 
this study were MPG and its variants (Table 4.2). 
 
 
4.3.1 Design of MPG modifications 
 
MPG-GFP can be translocated into C. albicans with very little killing (section 3.2). 
These translocation results logically support the idea of peptide residue substitutions. 
To understand the characteristics of the residues and their effect on translocation, Dr. 
Jeffery Klauda and his lab ran simulations and calculated the interaction energy of each 
residue of wild-type MPG with the membrane. The residue and their distance from the 
top membrane plane of the model membrane was also calculated (Figure 3.13).  
 Based on the experimental and simulation results presented in Chapter 3, we 
designed variants of MPG to evaluate for improved translocation. The residues S13 and 
T14 are both hydrophilic uncharged residues and do not contribute to translocation, as 
is seen from the computed interaction energies. We changed these residues to charged 






mid-region will help with binding of the peptide to the membrane and when the peptide 
moves into the membrane the charged residues will help transport it to the other side. 
CPPs have been known to have charges in the mid-region of the sequences22, 23, and, 
thus, modifying these residues (Table 4.3) would help increase translocation. Arginine 
and/or lysine will help conserve the hydrophilic nature at the particular sites and this 
will help us to identify the precise changes that affect translocation. 
 
Table 4.2. CPP variants used in this study 
*Includes charge due to amino acid side chains 
 
 As is evident from Figure 3.13, the charged residues at the C-terminus of the 
wild-type MPG (MPG only for simulation studies) stick to the membrane and do not 
go into the membrane whereas the hydrophobic residues at N-terminus help 
translocation. Though these charges help with the peptide’s attachment to the 
membrane, we have to make sure that the MPG-GFP (GFP is at attached at the C-
terminus of MPG in our experimental studies) fusion can translocate into the cells. We 
believe that altering some of the charged residues to hydrophobic residues is likely to 
help and introducing W19 in place of S19 to see the effect of this mutation on 
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translocation. We expect that a hydrophobic residue would help translocation of MPG-
GFP into the cells.  
  
4.3.2 Expression and purification of MPG variants 
 
The designed MPG variants were fused with GFP and produced recombinantly in E. 
coli. The variants were then purified with IMAC. There were some challenges with the 
expression and purification of S13K-GFP. Expression at 6 h and 37 °C were 
comparatively lower than other proteins. This could be attributed to the higher charge 
of the constructs and possible killing of E. coli cells thereby leading to lower 
production. This construct could possibly be induced for a longer time to enhance 
production. At the same time, the protein could be part of the insoluble portion. This 
could be due to protein misfolding, and re-solubilizing the insoluble portion could 
improve protein extraction. On the other hand, T14K-GFP could be produced well and 






   
4.3.3 Translocation of MPG variants into C. albicans cells 
 
The purified proteins were incubated with C. albicans for 1 h and 24 h hours at 30 °C 
in sodium phosphate buffer (NaPB). Translocation of the peptide fusions were 
evaluated using flow cytometry and was compared with the translocation of native 
MPG-GFP fusion to analyze the effect of peptide mutations on translocation. We 





Figure 4.1. Purification of T14K-GFP. CPP fused to GFP and were expressed in BL21 (DE3) 
cells at 37 °C for 6 h with 0.01 mM IPTG. Coomassie stain was used to estimate the purity of 
fusion proteins. Crude soluble lysates (L), flowthrough (FT), washes (W) and elution (E) from 
immobilized metal affinity chromatography are shown. Purification of T14K-GFP. The crude 
soluble lysate contains the whole construct; flow-through does not bind to the column and so 
flows through; elutes are obtained using a buffer that contains 50% imidazole. Molecular weight: 
CPP-GFP = 30.5 kDa. 
 
















Though T14K-GFP does not show higher GFP positive (%) cells, we were able 
to observe a higher percentage of PI positive (%) cells. As we know, cells are normally 
impermeable to PI, but PI fluorescence can be detected inside cells with destabilized 
membranes. Destabilization can occur with cell death or with pore formation on the 
membrane. On comparison with the cells, GFP and MPG-GFP, we could see cells at 
the same condition, we can argue that the cells died due to translocation of our T14K-
GFP fusion. But it should be noted that though there was higher PI positive uptake, 
GFP uptake was really low in case of T14K-GFP. The peptide might be interacting 
with the cells and permeabilizing the membrane without actually entering the cell. This 
could be beneficial if we can confirm that there is no toxicity to host cells, but the 
peptide-cargo fusion has antifungal properties. These data represent one replicate only 
and further experiments will need to be run to confirm our findings. 
 
 
Protein fusion  GFP positive (%) PI positive (%) 
GFP only 2.14 0.2 
MPG-GFP 7.2 0.526 






4.4 Discussion and conclusion 
 
We are using CPPs as delivery systems to deliver macromolecular cargo into the fungal 
pathogen C. albicans. We have successfully delivered protein cargo inside fungal cells. 
These experiments begin to explore the effect of CPP modifications on translocation of 
cargo and more work on evaluating more peptides and their variants will provide an 
improved understanding of properties of peptides that affect translocation. 
Further evaluation of the interaction of CPPs with Candida cells would provide 
insight into the biophysical properties that affect translocation, the mechanisms of 
translocation, and the toxicity of the peptides. Our initial data suggest that net charge 
of the peptides play a role in translocation, and further studies would help us in 
understanding the effect on translocation. Since, the phosphate heads of the membranes 
are negatively charged, it can be assumed that positive charged residues in peptides 
will lead to electrostatic interactions that would bring the residues in close contact with 
the cell membrane and affect translocation. 
Further studies of the peptides and the mammalian cells are necessary to 
understand the effect of the peptides on these cells. In the initial sets of data for T14K-
GFP, we observed a strong toxicity toward fungal cells which suggests that this peptide 
would be promising as antifungal agents. Future studies, could include just the peptide 
and compare its translocation efficacy with that of the peptide-cargo fusion. The 
concentration of the fusions should be increased to 200 µM (or higher) to compare with 






We have recognized CPPs that are able to translocate into C. albicans and 
deliver active biomolecular cargo. Our work explored the intracellular delivery of a 
macromolecular cargo into fungal cells. Our results suggest that biophysical properties 
of peptides play a role in translocation of CPPs into fungal cells and apply mechanisms 
that might lead to the toxicity to the cells. Further work could explore the translocation 
mechanisms of CPP-cargo fusions to improve their translocation efficacy into cells and 
study their toxicity profiles that can make CPPs viable therapeutic delivery agents. 
Improving the translocation of biomolecular functional cargo using CPPs, will ensure 
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Chapter 5: Aggregation of fusion proteins 
 
In the previous chapters, we have been able to successfully deliver a biomolecular 
cargo in C. albicans cells and have been able to use simulations as a tool to introduce 
changes into the peptides. Both simulations and experiments helped us study and 
explain the translocation mechanism of the peptides. In this chapter, we investigate 
factors like aggregation of fusions, that might affect translocation and list ways to 




As discussed in chapter 3, for our translocation studies, we have been using 
concentrations of proteins as high as 200 µM and even on concentrating the proteins 
further, I was not able to increase translocation of the fusions into Candida albicans. 
One possible cause of the lack of improvement would be that the CPPs are inactivated 
due to aggregation. In this chapter, we explore the aggregation of CPP-cargo fusions. 
This work was performed in collaboration with Shakiba Nikfarjam and Dr. Taylor 
Woehl. I probed the reasons why translocation did not increase with increasing 






affecting translocation at higher concentrations. The hypothesis here is that aggregation 
of the fusions could be inhibiting translocation. 
Aggregation of proteins includes a variety of interactions that occur due to 
different mechanisms and can be classified as soluble or insoluble, covalent or 
noncovalent, reversible or irreversible, and native or denatured2. Soluble aggregates 
can be defined as those that are not visible as distinct particles and may not be removed 
by a 0.22 μm filter2. Insoluble aggregates, on the other hand, might be removed by 
filtration and are often observable to the naked eye2. Protein aggregates can be divided 
into three sub-categories based on their size and solubility. Soluble aggregates consist 
of protein oligomers and aggregates that range from 10 nm to 100 nm; subvisible 
particles range from 100 nm to 100 μm; 100 nm to 1 μm particles are submicron; and 
particles over 100 μm in size can be classified as visible particles1, 3, 4. 
The challenges to overcome protein aggregation is one of the main problems in 
commercialization of drug products5. Native oligomers are highly stable and have 
possibly higher solubility than their monomers, and insulin in the presence of zinc ions 
is an example of a stable protein pharmaceutical product6. In most cases though, 
aggregation affects product quality. There are increasing concerns that patients can 
develop immune responses to the drug when they are partially folded, irreversible 
aggregates that remain in the blood stream7. Aggregates are not only responsible for 
drug product quality but can also cause many diseases. 
Proteins have a propensity to aggregate due to a variety of reasons8. Degree of 






quaternary structure or extrinsic environmental factors and processing conditions8. 
Protein aggregates can lead to reduced or a lack of biological activity that can lead to 
immunogenic response or other side effects8. This inherent tendency of proteins to 
aggregate makes their use in biological applications9-11. When proteins aggregate, they 
can sometimes form unwanted deposits9-11. In some diseases, for example, in 
Alzheimer’s, proteins which are usually soluble, form deposits10, 12. Protein aggregation 
have been known to cause a variety of other diseases like Parkinson’s and Huntington’s 
disease13. 
Aggregation has been studied using a number of optical methods. Microscopy 
methodologies have been used for imaging purposes and for quantification of particles. 
In fact, researchers have used fluorescence microscopy methods like confocal 
microscopy and total internal reflection fluorescence to image subvisible particles1, 14-
16. For pure optical scattering, scattering intensity (I) varies with particle radius (r) as 
𝐼	 ∝ 𝑟', which is a limitation to established optical methods as they cannot determine 
the weak scattering particles that have with sizes > ∼1 μm1, 17. This is where 
interferometric scattering microscopy can help. Interferometric scattering microscopy 
is an optical microscopy method that works on collecting light scattered by an object 
jointly with a reference light, specified by the reflection at an interface18. This method 








Using interferometric scattering microscopy, the proportionality is modified to 
𝐼	 ∝ 𝑟( that interferes with particle scattering when a reference wave is formed by using 
layered sensor chips17, 19. This method introduces a phase shift in the particle scattering 
which leads to increase in sensitivity to minute, low contrast particles. These images 
obtained from the optical microscope are easy to understand as there is a dependence 
of particle size and the scattering intensity and Dr. Taylor Woehl’s lab has been 
successful in using non-complex modeling techniques to process the images and extract 
information on particle size1, 20. This method has the capability to conserve high 
imaging contrast that does not depend on the exposure time or the scattering cross 
section of the object18. 
Another method that has been widely used to study aggregates dynamic light 
scattering (DLS). When a monochromatic beam of light points at any solution that 
contains macromolecules, the light disperses in all directions. This light scatters as a 
Figure 5.1. Schematic representation of multilayered interferometric scattering microscopy 
sensor to describe optical scattering and interference. A planewave (orange horizontal lines) 
disperses off of a protein aggregate (purple) and a silicon-silicon oxide interface that produces 
a reference wave (blue) which affects the scattered wave. This interference pattern is detected 
on a CMOS camera on a customized optical microscope. Figure directly taken from Figure 1 
of Wong et al.4 Reproduced with permission © 2020 American Pharmacists Association®. 







function of the size and shape of the macromolecule21. The scattered light can either be 
mutually destructive that cancel out, or mutually constructive and generates a 
detectable signal22. Intensity fluctuations of the scattered light, caused by Brownian 
motion of macromolecules in solution, are studied, and information on diffusion 
coefficient (D) and hydrodynamic size of macromolecules can be acquired21 (equations 
can be found in Section 5.4). Dynamic light scattering, measures the Brownian motion 
of macromolecules in solution, which happens due to the light hitting on the solvent 
molecules, and relates particle size to the diffusion coefficient. Motion of these 
macromolecules depends on the size, temperature, and solvent viscosity21, 22. 
Therefore, knowledge of precise temperature is crucial for DLS measurements22. 
Particle movement over a range of time is recorded and information on the size of 
macromolecules can be gained; large particles diffuse slowly, that results in analogous 
positions at different times as compared to small particles that move comparatively 
faster and do not assume a precise position22. A digital autocorrelator, correlates 
intensity fluctuations of scattered light to time to resolve intensity fluctuation, that can 
further be related to the diffusion of macromolecules22. 
5.2 Methods to study aggregation 
5.2.1 Purification of proteins  
 
25 mL of over-night culture for each construct was subcultured into 1000 mL of fresh 






at an optical density of OD600 = 0.05 and grown at 37°C for 2.5 h. The fusion protein 
expression was then induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) 
to each culture aliquot at a final concentration of 0.1 mM. The cultures were then 
incubated at 37°C for 6 h.  
After 6 h, cells were harvested by centrifugation, and the cells were resuspended 
in the buffer for purification (125 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA). 
The cells were then lysed using a homogenizer cell disruption system (Avestin). After 
lysis of each sample, the whole-cell lysates were pelleted by centrifugation at  
11,419 × g for 50 min at 4 °C, and the supernatants containing the soluble fraction of 
the cell lysates were collected. The soluble fraction of each lysate was passed through 
a 0.45 μm filter and applied to an IMAC Profinity Ni-NTA resin column (Bio-Rad). 
After thoroughly washing the column, the flowthrough and washes were collected. The 
proteins were eluted in a buffer containing 20 mM sodium phosphate (pH 7.4), 0.5 M 
potassium chloride (KCl), and 500 mM imidazole. After collecting the elutes, protein 
concentration was measured using Nanodrop (Thermo Scientific, USA) and the protein 
was concentrated using vivaspin 6 molecular weight cut-off (MWCO) columns at  
4,000 × g using a swinging bucket rotor (Beckman Coulter, Brea, CA). 
5.2.2 Dynamic light scattering (DLS) to study aggregation 
Protein samples were expressed E. coli and were purified using affinity 
chromatography. They were concentrated to 200 µM to match our translocation 






cuvettes. They were illuminated by a laser beam and the fluctuations of the scattered 
light were identified at a known scattering angle θ using a fast photon detector. 
Scattering of light by particles imprints information about their motion. The fluctuation 
of scattered light is analyzed and this yields information about particles. We 
experimentally characterized the intensity fluctuations by calculating the intensity 
correlation function g2(t)23: 
𝑔)	(𝑞, 𝜏) = 	
〈,!	(.,0)	,!	(.,02	3)〉	
〈|,!	(.,0)|#〉
			                         (Equation 5.1) 
 
where I is the intensity as function of time, t, and q is wave vector. This analysis 
compares the diffusion coefficient of the particle intensity 𝐼(𝑡) of the scattered light at 
a time t with that at some later time (𝑡 + 𝜏), 24, 25 where 𝜏 is the lag time between the 
two time points.  
For spherical monodisperse particles in a fluid, the autocorrelation function has 
a single characteristic decay time 𝜏: 
𝑔)	(	𝜏) = 		 〈1 + 𝑒𝑥𝑝(−2𝛤𝜏〉                        (Equation 5.2) 
 
The decay rate depends on the wave vector and thus the scattering angle. 𝛤 is 
proportional to the diffusion coefficient of the particles and is the inverse of the decay 
time, 𝜏6, as:  






where 𝑞 = (4𝜋𝑛 𝜆⁄ )sin	(𝜃 2)⁄  is the wave vector, n is refractive index, 𝜆		is the laser 
wavelength, and 𝜃 is the scattering angle. For spherical non-interacting particles, the 
particle size can be determined by converting the diffusion coefficient to hydrodynamic 




                                    (Equation 5.4) 
where kB is Boltzmann’s constant, T is the temperature, and 𝜂 is the viscosity of the 
solvent. A fixed scattering angle of 60° was chosen and the experiments were 
performed at room temperature. Viscosity was set to 0.89 cP with a refractive index of 
1.33.  
 
5.2.3 Interferometry to study aggregation 
 
The method for interferometry scattering microscopy is based on the method of Wong 
et al. 20191. The samples were made on multilayered sensors that consisted of a silicon 
wafer piece coated with a 20 nm thick layer of silicon oxide (SiO2). The starting 
material for the sensors was polished 100 mm silicon wafers that had a net thickness 
variation of <5 µm (Silicon Materials, Pittsburg, PA). A 110 nm thick SiO2 layer was 
added first, by a wet thermal oxidation process and then imprinted with a hydrofluoric 
acid wet etch to attain the preferred thickness. An SiO2 thickness of 20 nm was selected. 
Further, interferometric microscopy sensors were made by cutting the surface oxidized 






air and cleaned with plasma for 5 min in air plasma (Harrick Plasma, PDC32G) for 
removal of remaining solvent and surfactant. 10 µl of liquid protein aggregate sample 
was put onto the sensor surface, which was then dried at room temperature, followed 
by rinsing with deionized water. Drying of the sensor was done to ensure that the large 
refractive index difference between air and SiO2 intensifies the sensitivity of 
interferometry scattering microscopy1, 19.  
The interferometry scattering microscopy experiments were done on an altered 
upright optical microscope (Zeiss Axioscope) that was used in reflection mode. The 
modified design of the microscope incorporated a collimated 530 nm LED epi-
illumination source (Thorlabs, Newton, NJ, 150 mW)1. To guarantee plane wave 
illumination and uniform light intensity across the complete imaging field, Kohler 
illumination was used. The images were obtained using a 20X dry objective lens with 
a numerical aperture of 0.45. This was then projected onto a monochrome 1900 × 1200 
pixel CMOS camera with an exposure time of 1 ms (FLIR Grasshopper G3)1. To reduce 
the numerical aperture of the objective lens, a 1 mm diameter pinhole was introduced 
into the back focal plane. This adjustment increased the interferometry scattering 
microscopy image contrast by brightening the sample at low angles of incidence, which 
directed the scattered light directly onto the objective lens and not to wide angles, 
thereby reducing the background of the image1, 27. In the process of imaging the protein 
aggregates, they might dry which may make them change their size/shape but latest 
measurements of protein aggregate density have shown that density is related to the 






protein aggregates1, 28. This hints at the fact that submicron protein aggregates have 
very little porosity and thus their size is not affected due to drying1, 28.Results and 
Discussion 
 
5.2.4 Study of aggregation using dynamic light scattering 
 
To explore the presence of aggregates in GFP, MPG-GFP and Hst5-GFP, DLS was 
used to determine the presence of aggregates in our protein solutions at 200 µM in 
NaPB (Figure 5.1). The proteins were expressed in E. coli and purified by affinity 
chromatography. The proteins were then concentrated to 200 µM. DLS measurements 
were done at room temperature. The measurements of the hydrodynamic radius of the 











Figure 5.2. DLS analysis for correlation function and hydrodynamic radius. DLS correlation function (g2) obtained 
for (a) GFP, (b) MPG-GFP and (c) Hst5-GFP at 200 µM and intensity distribution for (d) GFP, (e) MPG-GFP and 











Table 5.1 Hydrodynamic radius analysis at protein concentrations of 200 µM in NaPB 




GFP 1 7.683 0.861 
 2 59.92 12.79 
MPG-GFP 1 8.058 1.975 
 2 59.55 20.90 
Hst5-GFP 1 10.48 2.308 
 2 82.75 29.40 
 
Hydrodynamic radius, is the radius of a comparable hard sphere that diffuses at 
the same rate as the molecule under study.  Protein solutions and their complexes do 
not actually exist as hard spheres, and, therefore, the hydrodynamic radius is the 
apparent size assumed by the protein molecule. As can be seen from Figure 5.2 and 
Table 5.1, the size of GFP and MPG-GFP are ~8 nm and that for Hst5-GFP monomers 
is ~10 nm. Erickson et al. have determined the size and shape of protein molecules by 
use of different techniques29. Sedimentation and gel filtration techniques can be used 
to better determine the size of our aggregates. Much bigger aggregates were found and 
the correlation function is a single exponential, which means that the protein solutions 
were dominated by the aggregates, that is there were more aggregates than smaller 
particles. The concentration of proteins used in this experiment is comparatively lower 
for DLS measurements than those normally measured in DLS studies, and the 
aggregates contributed the most for the recorded intensities detected here. One 
interesting fact to note here is that, the standard deviation of peak number 2 (peak for 
aggregates) for each protein was large, thus leading us to believe that an array of 






for GFP and MPG-GFP are comparable (<100 nm), the relative population of 
aggregates for Hst5-GFP were quite different. There were more aggregates compared 
to monomers for Hst5-GFP.  
 These analyses identify the presence of aggregates in our protein samples and 
suggest future experiments to gain additional information on the aggregates and 
aggregation process. Though scattering angle might not have any dependence on 
aggregation, it will be worthwhile to measure the hydrodynamic radius at different 
scattering angles and see the effect of scattering angle on the samples. Temperature is 
another parameter that can be varied and experiments can be performed at both higher 
temperatures (for example, 37 °C and 50 °C ) and lower (for example, 4 °C) to see the 
effect of temperature on aggregate formation. Our samples were filtered with 0.20 µm 
filters but further studies with 0.02 µm filters might help in removing aggregates from 
the solution. These would remove the smaller aggregates and we can have a stronger 
monomer peak. Experiments should be performed using these monomers to see their 
effect on translocation. These same experiments should also be done for a range of 
concentration, to understand the dependence of aggregation on concentration of 
proteins. Doing the DLS in parallel with the translocation experiments (experiments 
with flow cytometry as explained in chapter 3 and 4) could lead to an understanding of 
whether aggregation limits translocation.  






5.2.5 Study of aggregation using interferometric scattering microscopy 
 
To further study the presence of aggregates, initial studies with interferometric 
scattering microscopy were done with purified Hst5-GFP and MPG-GFP at a 
concentration of 200 µM. Dr. Woehl and his lab performed the experiments to identify 
aggregates in our samples. 10 µl of each of these proteins were applied on the chips 
and dried for 10 mins or higher depending on the time taken for drying. These were 










Fluorescent images of the proteins were taken and then analyzed for the 
presence of aggregates. Protein aggregates can be detected as small black spots in the 
image (Figure 5.3 (b), (d)). Protein aggregates are seen to immobilize on the surface of 
the sensor. Ultimately, the liquid layer got thinner than the protein aggregates and fixed 
them to the sensor surface. Additional buffer was washed away after cleansing with 
deionized water, and this process leaves the protein aggregates permanently attached 
to the sensor surface. Rinsing with deionized water remove the attached aggregates 
from the surface of the sensor and this could be attributed to electrostatic attraction 
between the positively charged aggregates and the negatively charged SiO2 surface with 
Figure 5.3. Interferometry images of Hst5-GFP and MPG-GFP. 10 µl of each protein was added 
to the chip, dried and washed with deionized water. Fluorescence and interferometric scattering 
images were captured. (a) fluorescence microscopy image of Hst5-GFP (b) interferometric 
scattering microscopy image of Hst5-GFP (c) fluorescence microscopy image of MPG-GFP (d) 
interferometric scattering microscopy image of MPG-GFP. The arrow points to a protein aggregate 









silanol groups. This makes sure that the aggregates remain attached to the sensor 
surface and can be observed under the microscope. 
“Coffee ring” effects were observed which leads us to believe that aggregates 
concentrate near the edges of the droplets. In general, it has been seen that for like-
charged particle/surfactant mixtures, the particles form a ring-shaped deposit, called 
“coffee-ring effect”30. During dropcasting, coffee-ring effect is a common occurrence. 
This happens due to solvent evaporation during film assembly that is stimulated by 
capillary flows in the drop which displace particles to the three-phase contact line, 
which results in particle accumulation at the dry film boundaries and thus the formation 
of coffee-ring like structure31.  
This initial study shows that our proteins aggregate and indicates the utility of 
interferometric scattering microscopy in studying CPP-cargo fusions. Additional 
experiments will identify optimal solution conditions to better image and quantify 
aggregates and study the effect of different concentrations of the proteins. We could 
also use image analysis to quantify the maximum scattering intensity for each particle 
on a 16-bit scale. These experiments would also allow us to quantify the particle size 









5.2.6 Possible ways of mitigating aggregation 
 
DLS and interferometric scattering microscopy show that the protein fusions are 
aggregating and, in addition to studying the aggregation, it will also be important to 
control it. This study presents a representative set of data to show which factors among 
many can affect translocation of proteins fusions into cells. Further characterization 
using analytical techniques like sedimentation velocity using an analytical centrifuge 
should be done to measure the size of the aggregates and gel filtration can be used to 
separate the different aggregate sizes. 
In this chapter, I have outlined various factors that during our experimental 
process could be contributing to aggregation of our proteins. For our future experiments 
we could focus on the various parameters like pH of a buffer solution, temperature, 
various stresses and shears that lead to aggregation and take measures and necessary 
steps to control them.  
Cell culture is the first stage in protein expression. For expression of proteins, 
E. coli is commonly used cell system and expression is done under a variety of 
conditions and proteins have been known to aggregate into inclusion bodies during 
expression in bacterial systems8, 32. Factors like temperature, protein concentration, 
type and concentration of denaturant, pH, ionic strength, refolding catalysts, 
thiol/disulfide agents, and miscellaneous additives8, 33-35 affect aggregation of proteins 






modulated by process conditions like temperature, use of surfactants, and other 
additives8, 36, 37. 
 To prepare proteins for purification after expression, we lyse the cells using a 
homogenizer in which we apply pressure to break open the cells to extract the protein 
lysate, and this process can induce aggregation. High pressure can cause protein 
unfolding and enable protein aggregation due to higher hydrophobic interactions2, 38, 39. 
Processes like shaking and shearing can induce aggregation but the aggregation 
depends on the time and intensity of exposure. If protein purification conditions are too 
harsh like pH of buffer, it can induce aggregation8, 40. Careful monitoring of process 
conditions during purification can help reduce aggregation. In our study, the 
purification of Hst5-GFP involved additional steps during purification. Factor Xa was 
used for off-column cleavage of GST, followed by introduction of the lysate to the 
chromatography column. While concentrating the proteins to the required 
concentration, the number of centrifugation cycles for each protein was different (for 
example, it needed much less time to concentrate GFP to 200 µM as compared to both 
MPG-GFP and Hst5-GFP) , and  that could be a contributing factor too. Aggregates 
that are formed during cell culture or in any of the processing steps, might be removed 
during the purification procedure by manipulating the differences in various properties 
of the monomers and aggregates, that includes surface charge, hydrophobicity, and 
size2.  
 Protein concentration has been attributed as a key factor that promotes protein 






result in the following: (1) decrease in aggregation due to overcrowding; (2) increase 
in aggregation due to increased association; and (3) precipitation due to limit of 
solubility8. Crowding favors formation of compact conformations that has the tendency 
to reduce aggregation8. However, increasing protein concentrations increases protein 
association that accelerates aggregation. Protein have a solubility limit, that depends 
on the solution. When protein concentration exceeds this solubility limit proteins have 
a tendency to aggregate and crash8, 41. In our experiments, we use a concentration of 
200 µM which is high enough to observe aggregation via various experimental 
methods.  
Protein aggregation can be varied by numerous solution conditions that play a 
critical role. pH of a solution is one of the most important factors that can alter protein 
aggregation. The surface charge of proteins in solution depends on the solution pH, and 
it affects both intramolecular folding interactions and intermolecular protein–protein 
interactions8. Altering the solution pH might change the aggregation rate-limiting steps 
and the mechanisms and pathways of formation of aggregates and thus, the morphology 
of protein aggregates42. A buffering agent can be used to preserve the optimum pH for 
stability. Filtration of the proteins might also help to take out insoluble aggregates. Size 
exclusion chromatography and gel electroporation could be used in conjunction to 
identify larger aggregates and their removal.  
 Translocation studies should be attempted with just the protein monomer or 
lower-order oligomers and see their effect on translocation. Protein concentration is 






the other factors which are greatly responsible for aggregation of our proteins, we 
would be able to have control measures to avoid aggregation, even at higher 
concentration. It would also be worthwhile to check if the aggregation is reversible i.e., 




5.3 Conclusion  
 
The purpose of this study was to determine if our protein samples at higher 
concentrations (concentrations at which translocation studies in chapter 3 were done) 
formed aggregates. Using both DLS and interferometry we were able to identify 
aggregates at concentration of 200 µM. These techniques are reliable methods to 
observe and quantify aggregation, and further studies are warranted to expand on our 
findings and relate them to translocation. Additionally, we outline potential ways to 
reduce aggregation in future experiments with CPP-GFP fusions. To reduce protein 
aggregation, we can choose an array of experiments and modulate the temperature, 
concentrations of proteins, pH of our buffers and monitor the conditions. With this 
study, we gain knowledge and understanding on aggregation and factors affecting 
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Chapter 6: Conclusion and future work 
 
In this thesis, we have improved the understanding of CPP-cargo fusions and how they 
interact with Candida albicans. In Chapters 3 and 4, we established that CPPs can be 
used to deliver functional larger cargo into Candida cells. Some initial studies show 
that the cargo has a more pronounced effect on the secondary structure of the fusion 
than the peptide. Preliminary simulation studies, have enabled us to rationally design 
CPPs to study translocation and help understand the structure-function relationship. In 
Chapter 5, we show that our fusion proteins aggregate at our concentrations of 200 µM 
and further studies could help relate this to translocation. Our work has substantial 
impact for understanding CPP-mediated delivery of biomolecular cargo fusions in 
fungal pathogens that provides the motivation for additional work to further explore 
the limitations of cargo delivery into fungal pathogens and ways to make it better. In 
this chapter, we discuss suggestions for future studies for detection of non-fluorescent 
cargo. We have described how Western blot and split-protein assays can be used to 
detect non-fluorescent cargos. Additionally, we have outlined design strategies to 
enhance properties of peptides and proteins by the use of protein engineering 








6.1 Detection of fusions inside Candida albicans cells for non-fluorescent cargo  
 
So far, we have studied translocation into Candida using GFP as our cargo, using flow 
cytometry, but such translocation assays cannot be used for non-fluorescent cargo. 
Techniques like flow cytometry, fluorescent microscopy and other fluorescent 
techniques use fluorescent molecules to quantitatively detect the translocation into 
cells. Fluorescent techniques involve the use of either fluorescently labeled peptides or 
cargo. The labeled peptides are expensive to synthesize and site-specific conjugation 
of the peptide to the cargo might not be specific2. Also, a large number of cargoes are 
non-fluorescent, and approaches need to be developed to detect them inside cells. This 
motivated us to use Western blot as an alternate detection method.  
 
6.1.1 Detection of fusions inside Candida albicans cells for non-
fluorescent cargo using Western blot   
 
Preliminary studies to detect fusions using Western blot have been done, with GFP 
using HRP-conjugated anti-GFP by Western blot (Figure 6.1), and validate our results 
obtained from flow cytometry. Samples for Western blot were prepared similar to the 






Protein samples were 
mixed with cell 
suspension and 
incubated at 30 °C for 
24 h. After 24 h, the 
cells were washed 
with NaPB, and then 
incubated with 200 
μL of 0.025 % trypsin 
(Invitrogen) at 37 °C for 30 mins to remove surface-bound proteins. Next, cells were 
washed and re-suspended in 250 μL of 10 mM NaPB and were then pelleted by 
centrifugation. Cells were then, resuspended in a required amount of Y-PER Reagent 
(ThermoFisher Scientific), according to the manufacturer’s protocol. Y-PER is a 
chemical lysis agent to that helps to separate the proteins from the cells. Proteins in the 
soluble cell lysate were then recovered and separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were 
transferred to a polyvinyl difluoride (PVDF) membrane using a transblot (BioRad) and 
stained with horseradish peroxidase (HRP)-conjugated anti-GFP antibody (Abcam) to 
identify the proteins inside the cell. Densitometry analysis was done on the Western 
blot, using ImageLab software (Version 5.2; Bio-Rad) to evaluate the relative 
translocation level based on the signal of the detected bands. A one-way ANOVA 
analysis (GraphPad Prism 7.03) was used for statistical analysis to measure the 
Figure 6.1. Detection of proteins inside C. albicans using anti-
GFP. The protein fusions were expressed in E. coli BL21(DE3). 
Soluble cell lysates were prepared using Y-PER reagent and 
analyzed by Western blot. The samples were normalized by 
culture volume. Proteins were detected using an HRP-conjugated 
anti-GFP antibody. The relative translocation level confirmed that 
MPG-GFP translocation was significantly better than Hst5-GFP 
(p ≤ 0.001). Molecular weights: GFP = 27 kDa, Hst5-GFP = 
30.010 kDa, MPG-GFP = 30.500 kDa. Densitometry analysis 











statistical significance of each construct. The relative translocation level confirmed that 
MPG-GFP translocation was significantly better than Hst5-GFP (p ≤ 0.001).  
 Though we have successfully detected the fusions inside C. albicans using 
Western blot, we are limited in evaluation of translocation and cannot evaluate function 
of the translocated protein. Another limitation is that we only get the average 
translocation for cells as a group, and individual cell data is not available and Western 
blot is not particularly quantitative. It is crucial to demonstrate that the internalized 
peptide-cargo fusions are capable of mediating biological functions once they are inside 
the cells. We do not have much evidence on cytosolic delivery and appropriate 
biological availability of the cargo delivered by the CPP, except that GFP remains 
fluorescent. While Western blot is cheap, easy to use, and produces quick results, there 
is no information available on localization data. We require a way to visualize any 
cargo, both fluorescent and non-fluorescent by a common technique to be able to 
compare between translocation and a split protein complementation assay is a 







6.1.2 Split complementation assay for assessment of functional delivery 
of cargo  
 
Our suggested approach is to use a split-protein complementation assay. In a split 
protein complementation assay, a protein (e.g., GFP) is split into two separate parts and 
become functional only when they come together (Figure 6.1)1.  
 
Two fragments of GFP would work well for this approach. We would fuse CPP 
to the smaller fragment of GFP, and this fusion would be produced in E. coli., and the 
other fragment will be produced in our target organism. When these two fragments 
come together inside the target cells (Figure 6.2) they exhibit fluorescence. By fusing 
our cargo protein to the CPP-smaller fragment, we could identify delivery of any non-
fluorescent cargo by measuring GFP fluorescence. This method will allow future 
studies more dedicated to the localization and function of any delivered cargo. 
 
Figure 6.2. Representation of GFP complementation. Fluorescence is detected when the 








To design our system, we will use the template used by Cabantous et al. to 
detect uptake of our proteins3, 4. The self-assembling split-GFP protein-solubility 
assay3, 4 will be designed as follows, using the GFP fragments designed by Cabantous 
et al.: GFP1-10 , the larger protein fragment, will be expressed in the cytosol of the target 
cells while the smaller GFP11 protein fragment will be fused to a CPP-cargo comprising 
moiety. The CPP fusion to a fragment of GFP, will guarantee that the complementation 
will happen if the fusion goes across the cell membrane and enters the cytoplasm to 
self-assemble into fluorescent GFP molecules (Figure 6.3).  
I recommend starting with experiments for translocation in Saccharomyces 
cerevisiae, since it is a well-studied genetic model5, before moving into C. albicans 
where heterologous protein expression will be more challenging6. We will produce the 
larger GFP1-10 fragment in S. cerevisiae. We will investigate the complementation 
signals made in the cells with the different fragments GFP1-10 and CPP-GFP11 
Figure 6.3. Protein-protein interactions. Fragment GFP1-10 and GFP11 are separately produced 
and are non-fluorescent but when they come together and they exhibit the classic fluorescence 






constructs and quantify GFP complementation with a fluorescence plate reader, flow 




With GFP1–10 being expressed in the cytoplasm, fluorescence will only appear 
when the CPP-GFP11 fusion penetrates and enters the cytoplasm and combines with 
GFP1-10, to form the fluorescent molecule (Figure 6.3). This has the added advantage 
of confirming the delivery of the cargo protein to a location in the cell, and exert its 
biological function, rather than being trapped in the endosome. The split-GFP-based 
assay will be suitable for studying the translocation of a smaller sized cargo, and a non-
fluorescent cargo that can be converted to into something that will be fluorescent inside 
the cell.  
 
 
Figure 6.4. Illustration of GFP complementation assay. Fluorescence is detected when CPP-
protein fused to S11-peptide penetrates the cell membrane to complement cytosolic GFP1-10 







6.2 Use of Directed evolution to design CPPs for enhanced translocation 
 
In chapter 2, I outlined protein engineering techniques that can be used to enhance 
peptide properties. Once such technique is the use of directed evolution. It imitates 
natural selection, and a large library can be generated by creating random or targeted 
mutations into the gene for any peptide. This library can then be exposed to multiple 
screening rounds and mutagenesis, and favorable mutants can be isolated from the first 
round and these mutants can be used as the basis for the next round and so on7, 8. These 
rounds of selection can continue until desired mutants with desired fitness have been 
achieved8-10. With directed evolution you have the flexibility of choosing the 
characteristic(s) you want to design for and iterating the screening until you achieve 
the required accuracy. Directed evolution has the advantage that is that there is no need 
to understand the mechanism of the desired activity or how mutations affect this 
activity11. But choosing the right screening technique is of utmost importance. Only a 
single variant is in each well, and, thus, genotype-to-phenotype linkage can be 
maintained. Display techniques like cell-surface display and in vitro display bring 
provide the ability to screen large numbers of variants to directed evolution, but 
reducing the library size can help to screen a library with less resources. Saturation 
mutagenesis would help us to use the combination of rational design and directed 
evolution. In site-saturation mutagenesis, peptides are screened for desirable fitness 
with all 20 canonical amino being sampled at the residue(s) of importance12, 13. We will 






resulting library can be screened for the best mutant. The best mutants can then be 
subjected to another round of mutagenesis. The peptides can be fluorescently labeled 
and We can use a fluorescent plate reader, incubate our labeled peptides with our cells 
and study their uptake (follow similar experimental procedure as for translocation 
studies in Chapters 3 and 4). For the mutants that translocated more into our cells, a 
second round of mutagenesis can lead to better peptides and so on. 
 
6.3 Use of machine learning as a tool to design new and better CPPs to target 
fungal pathogens 
 
Machine learning can be used to improve characteristics of peptides. A database of 
peptides can be used to train a model by finding patterns in a given set of peptides. The 
trained model can then generate new peptides with the preferred criteria. Machine-
learning imitates directed evolution and helps selection of peptide with desirable 
fitness14-17. This section talks about the use of machine to design new peptides to target 
fungal pathogens. The ideas in this section were developed in collaboration with Mahdi 
Ghorbani. 
With the growing research in the field of CPPs, predictive models can 
differentiate between whether a sequence of peptide is antifungal or antimicrobial in 
general, and this in turn reduces the cost of commercial synthesis and the experimental 






learning (ML) models like support vector machines (SVM), and random forest (RF) 
have received a lot of attention in recent years due to their ability to distinguish between 
positive and negative examples with improved precision14, 18-20. We would use ML 
methods to predict the antifungal activity of peptides, and also generate peptide 
sequences that are not degradable by enzymatic degradation and distinguish peptides 
that have synergy with current antifungal drugs. Herein, the following features will be 
used to characterize our peptides and differentiate them from non-CPPs: 
hydrophobicity, charge, amino acid frequency, amino acid repeats, number of arginine 
residues, size, hydrophilicity, sequence length, dipeptide frequencies, amino acid 
length, and tripeptide. 
 We would need to first generate a library based on experimental results. We 
would screen peptides for their activity as CPPs in C. albicans cells using experimental 
techniques like flow cytometry and fluorescence microscopy. Once we have a general 
data set of positive and negative examples, we will use ML to test antimicrobial 
peptides and classify them as CPPs vs. non-CPPs based on their translocation into 
mammalian cells, and fungal cells with the potential to function as peptide permeable 
into fungal cells without any toxicity to mammalian cells. This aim will help identify 
CPPs that can translocate into fungal cells and will warrant the development of 
preliminary structure‐functional relationships for translocation into fungal cells. We 
will use known CPPs and known non-CPPs from the literature to serve as our library 
of positive and negative data-sets and use a variety of features to list and find potential 






peptides - DRAMP22, toxic peptides – ToxinPred23, non-toxic or random peptides from 
SwissProt and TrEMBL23. Gupta et al., saw that residues such as Cys, His, Asn, and 
Pro were abundantly present and favored at different locations in toxic peptides23. We 
will further use BLAST to find regions of similarity between biological sequences24. 
The Basic Local Alignment Search Tool (BLAST) finds regions of local similarity 
between sequences24. The program compares nucleotide or protein sequences to 
sequence databases and calculates the statistical significance of matches. BLAST can 
be used to infer functional and evolutionary relationships between sequences as well as 
help identify members of gene families24. We will use SVM and RF, and use the models 
on the datasets listed above and on the basis of the features mentioned before, we will 
predict the model with the best accuracy. This will help us to recognize features that 
make a peptide sequence antifungal and non-toxic to human cells and it can be used as 
a design criterion for CPPs. To exert antifungal activity, these peptides need to cross 
the cell barrier and thus behave as cell-penetrating peptides. To help generate better 
CPPs we can apply machine learning and determine features that make peptides 
antifungal and utilize it to cause random mutations to increase translocation into fungal 








6.4 Evaluation of CPP-mediated translocation with C-terminal attachment of 
cargo  
 
Our experiments and simulations result in Chapter 3 have shown that MPG can enter 
C. albicans cells and deliver functional cargo inside the cells. In our preliminary 
experiments, we have studied the delivery of GFP into C. albicans cells. We 
recombinantly produced the proteins at 37 °C for 6 h based on my previous study25, 
and purified the CPP-cargo constructs to study their translocation into Candida using 
flow cytometry. In our studies with the different CPPs, MPG preferentially delivered 
GFP but Hst5 was not able to. At the same time, simulation studies in Chapter 3 
(Section 3.3.1) show that MPG entered the model yeast membrane but Hst5 remained 
attached to the membrane and did not go in. The simulation studies hinted on the fact 
that MPGs amphipathic structure, with N-terminal hydrophobicity made the transfer 
possible26. All our current constructs have a C-terminal attachment of cargo (Figure 
6.5) but Gong et al.27 has shown higher translocation with a smaller cargo but a N-
terminal attachment. To understand the factors affecting the translocation, for example, 
CPP structure, sequence, placement of cargo, further studies need to be done to decide 
on the right placement of cargo in a CPP-cargo fusion construct. Thus, one proposed 
idea would be to design constructs with GFP attached on the N-terminus, followed by 










This study will help us in understanding whether the placement of cargo has any 
implications on the translocation into fungal cells. This study can further shed light on 











Figure 6.5. Construct design for translocation into C. albicans. (a) Design of current constructs with a 
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Table A1 - Statistical analysis of Measurement of relative 
fluorescence unit (RFU)  




95% CI of diff. Significance Summary 
     
  450 (nm)     
GFP vs. MPG-GFP -10.7 -11289 to 11268 No ns 
GFP vs. Hst5-GFP -1.738 -11280 to 11277 No ns 
MPG-GFP vs. Hst5-GFP 8.958 -11269 to 11287 No ns 
     
  460 (nm)     
GFP vs. MPG-GFP -45.09 -11323 to 11233 No ns 
GFP vs. Hst5-GFP -26.06 -11304 to 11252 No ns 
MPG-GFP vs. Hst5-GFP 19.03 -11259 to 11297 No ns 
     
  470 (nm)     
GFP vs. MPG-GFP -1449 -12727 to 9830 No ns 
GFP vs. Hst5-GFP -929.8 -12208 to 10349 No ns 
MPG-GFP vs. Hst5-GFP 519.1 -10759 to 11797 No ns 
     
  480 (nm)     
GFP vs. MPG-GFP -9846 -21124 to 1432 No ns 
GFP vs. Hst5-GFP -5313 -16592 to 5965 No ns 
MPG-GFP vs. Hst5-GFP 4533 -6746 to 15811 No ns 
     
  490 (nm)     
GFP vs. MPG-GFP -4890 -16168 to 6388 No ns 
GFP vs. Hst5-GFP -89.46 -11368 to 11189 No ns 
MPG-GFP vs. Hst5-GFP 4801 -6478 to 16079 No ns 
     
  500     
GFP vs. MPG-GFP -2962 -14241 to 8316 No ns 
GFP vs. Hst5-GFP -5155 -16433 to 6124 No ns 
MPG-GFP vs. Hst5-GFP -2192 -13471 to 9086 No ns 






  510 (nm)     
GFP vs. MPG-GFP -2136 -13415 to 9142 No ns 
GFP vs. Hst5-GFP -7951 -19230 to 3327 No ns 
MPG-GFP vs. Hst5-GFP -5815 -17093 to 5463 No ns 
     
  520 (nm)     
GFP vs. MPG-GFP 21762 10484 to 33040 Yes **** 
GFP vs. Hst5-GFP 15819 4540 to 27097 Yes ** 
MPG-GFP vs. Hst5-GFP -5943 -17222 to 5335 No ns 
     
  530 (nm)     
GFP vs. MPG-GFP 17105 5826 to 28383 Yes ** 
GFP vs. Hst5-GFP 12659 1380 to 23937 Yes * 
MPG-GFP vs. Hst5-GFP -4446 -15725 to 6832 No ns 
     
  540 (nm)     
GFP vs. MPG-GFP 13283 2005 to 24562 Yes * 
GFP vs. Hst5-GFP 9167 -2111 to 20445 No ns 
MPG-GFP vs. Hst5-GFP -4116 -15395 to 7162 No ns 
     
  550 (nm)     
GFP vs. MPG-GFP 9289 -1989 to 20567 No ns 
GFP vs. Hst5-GFP 7056 -4223 to 18334 No ns 
MPG-GFP vs. Hst5-GFP -2233 -13511 to 9045 No ns 
     
  560 (nm)     
GFP vs. MPG-GFP 5649 -5629 to 16928 No ns 
GFP vs. Hst5-GFP 4400 -6879 to 15678 No ns 
MPG-GFP vs. Hst5-GFP -1250 -12528 to 10029 No ns 
     
  570 (nm)     
GFP vs. MPG-GFP 3441 -7838 to 14719 No ns 
GFP vs. Hst5-GFP 2707 -8571 to 13985 No ns 
MPG-GFP vs. Hst5-GFP -733.6 -12012 to 10545 No ns 
     
  580 (nm)     
GFP vs. MPG-GFP 2002 -9277 to 13280 No ns 
GFP vs. Hst5-GFP 1576 -9703 to 12854 No ns 







Table A2 - Statistical analysis of Relative translocation – 
comparison between samples   
Tukey's multiple comparisons test Mean Difference 95% CI of diff. Significant Summary 
     
cells only     
1 h vs. 4 h -0.5144 -3.265 to 2.237 No ns 
1 h vs. 18 h 4.005 1.254 to 6.756 Yes ** 
1 h vs. 24 h 2.801 0.05048 to 5.552 Yes * 
4 h vs. 18 h 4.519 1.768 to 7.270 Yes *** 
4 h vs. 24 h 3.316 0.5649 to 6.067 Yes * 
18 h vs. 24 h -1.203 -3.954 to 1.548 No ns 
     
cells +methanol     
1 h vs. 4 h 0.669 -2.082 to 3.420 No ns 
1 h vs. 18 h 2.12 -0.6310 to 4.871 No ns 
1 h vs. 24 h 1.973 -0.7776 to 4.724 No ns 
4 h vs. 18 h 1.451 -1.300 to 4.202 No ns 
4 h vs. 24 h 1.304 -1.447 to 4.055 No ns 
18 h vs. 24 h -0.1467 -2.898 to 2.604 No ns 
     
cells + GFP     
1 h vs. 4 h -1.315 -4.066 to 1.436 No ns 
1 h vs. 18 h 1.308 -1.443 to 4.059 No ns 
1 h vs. 24 h 1.74 -1.011 to 4.491 No ns 
4 h vs. 18 h 2.623 -0.1280 to 5.374 No ns 
4 h vs. 24 h 3.055 0.3040 to 5.806 Yes * 
18 h vs. 24 h 0.432 -2.319 to 3.183 No ns 
     
cells + MPG-GFP     
1 h vs. 4 h -1.272 -4.023 to 1.479 No ns 
1 h vs. 18 h 1.4 -1.351 to 4.151 No ns 
1 h vs. 24 h 0.8547 -1.896 to 3.606 No ns 
4 h vs. 18 h 2.672 -0.07932 to 5.423 No ns 
4 h vs. 24 h 2.126 -0.6246 to 4.877 No ns 






     
cells + Hst5-GFP     
1 h vs. 4 h -0.3413 -3.092 to 2.410 No ns 
1 h vs. 18 h 1.545 -1.206 to 4.296 No ns 
1 h vs. 24 h 1.469 -1.282 to 4.220 No ns 
4 h vs. 18 h 1.887 -0.8643 to 4.638 No ns 
4 h vs. 24 h 1.81 -0.9410 to 4.561 No ns 







Table A3 - Statistical analysis of Relative translocation – 
comparison between time points   
Tukey's multiple comparisons test Mean Difference 95% CI of diff. Significant Summary 
     
1 h     
cells only vs. cells +methanol -94.61 -99.11 to -90.11 Yes **** 
cells only vs. cells + GFP 2.462 -2.040 to 6.964 No ns 
cells only vs. cells + MPG-GFP 2.411 -2.091 to 6.913 No ns 
cells only vs. cells + Hst5-GFP 2.234 -2.268 to 6.736 No ns 
cells +methanol vs. cells + GFP 97.07 92.57 to 101.6 Yes **** 
cells +methanol vs. cells + MPG-GFP 97.02 92.52 to 101.5 Yes **** 
cells +methanol vs. cells + Hst5-GFP 96.84 92.34 to 101.3 Yes **** 
cells + GFP vs. cells + MPG-GFP -0.05133 -4.553 to 4.451 No ns 
cells + GFP vs. cells + Hst5-GFP -0.2287 -4.731 to 4.273 No ns 
cells + MPG-GFP vs. cells + Hst5-
GFP -0.1773 -4.679 to 4.325 No ns 
     
4 h     
cells only vs. cells +methanol -93.42 -97.93 to -88.92 Yes **** 
cells only vs. cells + GFP 1.662 -2.840 to 6.164 No ns 
cells only vs. cells + MPG-GFP 1.654 -2.848 to 6.156 No ns 
cells only vs. cells + Hst5-GFP 2.407 -2.095 to 6.909 No ns 
cells +methanol vs. cells + GFP 95.09 90.58 to 99.59 Yes **** 
cells +methanol vs. cells + MPG-GFP 95.08 90.58 to 99.58 Yes **** 
cells +methanol vs. cells + Hst5-GFP 95.83 91.33 to 100.3 Yes **** 
cells + GFP vs. cells + MPG-GFP -0.008 -4.510 to 4.494 No ns 
cells + GFP vs. cells + Hst5-GFP 0.745 -3.757 to 5.247 No ns 
cells + MPG-GFP vs. cells + Hst5-
GFP 0.753 -3.749 to 5.255 No ns 
     
18 h     
cells only vs. cells +methanol -96.49 -101.0 to -91.99 Yes **** 
cells only vs. cells + GFP -0.2346 -4.737 to 4.267 No ns 
cells only vs. cells + MPG-GFP -0.1939 -4.696 to 4.308 No ns 
cells only vs. cells + Hst5-GFP -0.2259 -4.728 to 4.276 No ns 






cells +methanol vs. cells + MPG-GFP 96.3 91.80 to 100.8 Yes **** 
cells +methanol vs. cells + Hst5-GFP 96.27 91.76 to 100.8 Yes **** 
cells + GFP vs. cells + MPG-GFP 0.04067 -4.461 to 4.543 No ns 
cells + GFP vs. cells + Hst5-GFP 0.008667 -4.493 to 4.511 No ns 
cells + MPG-GFP vs. cells + Hst5-
GFP -0.032 -4.534 to 4.470 No ns 
     
24 h     
cells only vs. cells +methanol -95.44 -99.94 to -90.93 Yes **** 
cells only vs. cells + GFP 1.401 -3.101 to 5.903 No ns 
cells only vs. cells + MPG-GFP 0.4642 -4.038 to 4.966 No ns 
cells only vs. cells + Hst5-GFP 0.9009 -3.601 to 5.403 No ns 
cells +methanol vs. cells + GFP 96.84 92.33 to 101.3 Yes **** 
cells +methanol vs. cells + MPG-GFP 95.9 91.40 to 100.4 Yes **** 
cells +methanol vs. cells + Hst5-GFP 96.34 91.83 to 100.8 Yes **** 
cells + GFP vs. cells + MPG-GFP -0.9367 -5.439 to 3.565 No ns 
cells + GFP vs. cells + Hst5-GFP -0.5 -5.002 to 4.002 No ns 
cells + MPG-GFP vs. cells + Hst5-
GFP 0.4367 -4.065 to 4.939 No ns 








Table A4 - Statistical analysis of Measurement of relative 




Difference 95% CI of diff. Significant Summary 
Adjusted P 
Value 
      
GFP only vs. MPG-GFP -8347000 -1.272e+007 to -3.970e+006 Yes ** 0.0027 
GFP only vs. Hst5-GFP 4124000 -252305 to 8.501e+006 No ns 0.0623 
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